ifosfamide has been researched along with Neutropenia in 142 studies
Neutropenia: A decrease in the number of NEUTROPHILS found in the blood.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In most countries, reference chemotherapy for osteosarcoma is MAP regimen (M = high-dose methotrexate, AP = doxorubicin-cisplatinum)." | 9.27 | Results of methotrexate-etoposide-ifosfamide based regimen (M-EI) in osteosarcoma patients included in the French OS2006/sarcome-09 study. ( Bompas, E; Bouvier, C; Brisse, HJ; Brugieres, L; Castex, MP; Cheurfa, N; Corradini, N; Delaye, J; Entz-Werlé, N; Gaspar, N; Gentet, JC; Italiano, A; Le Deley, MC; Lervat, C; Marec-Berard, P; Mascard, E; Occean, BV; Pacquement, H; Piperno-Neumann, S; Redini, F; Saumet, L; Schmitt, C; Tabone, MD; Verite-Goulard, C, 2018) |
| "Doxorubicin and ifosfamide are highly active drugs for the treatment of high-grade sarcomas, but little is known on the optimal management of young patients who develop such malignancies during pregnancy." | 9.16 | Doxorubicin and ifosfamide for high-grade sarcoma during pregnancy. ( Berrada, N; Bonvalot, S; Boulet, B; Cioffi, A; Domont, J; Le Cesne, A; Lokiec, F; Mir, O; Terrier, P; Trichot, C, 2012) |
| "A total of 143 patients with relapsed (n = 90), primary refractory (n = 32) and first line chemotherapy responsive (n = 21) non-Hodgkin lymphoma (NHL) and Hodgkin disease (HD) were treated with IVE (ifosphamide, etoposide and epirubicin) chemotherapy with the intent to proceed to high-dose therapy with either autologous or allogeneic transplantation, following peripheral blood stem cell mobilisation." | 9.12 | Ifosphamide, etoposide and epirubicin is an effective combined salvage and peripheral blood stem cell mobilisation regimen for transplant-eligible patients with non-Hodgkin lymphoma and Hodgkin disease. ( Bishton, MJ; Byrne, JL; Haynes, AP; Lush, RJ; Russell, NH; Shaw, BE, 2007) |
| "The relative value of increasing ifosfamide dose in combination chemotherapy for patients with soft tissue sarcoma (STS) is unclear." | 9.11 | Randomized phase II evaluation of 6 g/m2 of ifosfamide plus doxorubicin and granulocyte colony-stimulating factor (G-CSF) compared with 12 g/m2 of ifosfamide plus doxorubicin and G-CSF in the treatment of poor-prognosis soft tissue sarcoma. ( Baker, LH; Biermann, JS; Chugh, R; Leu, KM; McGinn, CJ; Sondak, VK; Taylor, JM; Worden, FP; Zalupski, MM, 2005) |
| "Our aim was to determine the efficacy of ifosfamide, mesna, and interferon alpha combination therapy in malignant mesothelioma (MM) patients." | 9.11 | Ifosfamide, mesna, and interferon-alpha2A combination chemoimmunotherapy in malignant mesothelioma: results of a single center in central anatolia. ( Altinbas, M; Coskun, HS; Ekici, E; Er, O; Eser, B; Gulmez, I; Kaplan, B; Ozesmi, M; Ozkan, M, 2004) |
| "The objectives of this trial were to estimate the response rate, progression-free survival, and overall survival of patients who received therapy with etoposide and high-dose ifosfamide, and to define the toxicity of this combination when provided with standard chemotherapy in patients with newly diagnosed metastatic osteosarcoma." | 9.10 | Phase II/III trial of etoposide and high-dose ifosfamide in newly diagnosed metastatic osteosarcoma: a pediatric oncology group trial. ( Bernstein, M; Devidas, M; Ferguson, W; Gebhardt, MC; Goorin, AM; Grier, HE; Harris, MB; Link, M; Schwartz, CL; Siegal, GP, 2002) |
| "A prospective trial to evaluate the efficacy and toxicity of ifosfamide (IFX) and vinorelbine (VNB) in patients with prior anthracycline therapy for metastatic breast cancer (MBC) was conducted." | 9.09 | Ifosfamide and vinorelbine in metastatic breast cancer in patients with prior anthracycline therapy. ( Aziz, Z; Qazi, S; Rehman, A, 1999) |
| "Adriamycin (ADM) and ifosfamide (IFO) are the two most active agents in the treatment of soft tissue sarcomas (STS) with a clear dose-response relationship." | 9.08 | High-dose ifosfamide plus adriamycin in the treatment of adult advanced soft tissue sarcomas: is it feasible? ( Aapro, MS; De Braud, F; De Pas, T; Fazio, N; Goldhirsch, A; Munzone, E; Nolè, F; Orlando, L; Zampino, MG, 1998) |
| "28 patients with recurrent advanced breast cancer were treated with a salvage regimen consisting of vincristine, epirubicin and ifosfamide/mesna (VIE)." | 9.08 | Continuous infusion of vincristine, ifosfamide and epirubicin over 6 weeks in treatment-resistant advanced breast cancer. ( Gurney, H; Harnett, P; Kefford, R; Stuart-Harris, R, 1995) |
| "The study was designed to assess the toxicity and activity of high-dose ifosfamide (HDI) administered by continuous infusion at a dose of 4 g/m2/d over 3 days every 4 weeks in adult patients with advanced soft tissue sarcomas (ASTS) pretreated with doxorubicin and/or a standard-dose ifosfamide (SDI)-containing regimen." | 9.08 | High-dose ifosfamide: circumvention of resistance to standard-dose ifosfamide in advanced soft tissue sarcomas. ( Antoine, E; Brain, E; Fontaine, F; Genin, J; Janin, N; Kayitalire, L; Le Cesne, A; Le Chevalier, T; Spielmann, M; Toussaint, C, 1995) |
| "Twenty patients with locally advanced or metastatic breast cancer were treated with four cycles of ifosfamide/mesna 5 g m-2 and epirubicin 60 mg m-2 every 14 days with granulocyte colony-stimulating factor (G-CSF, Filgrastim)." | 9.08 | The use of granulocyte colony-stimulating factor to deliver four cycles of ifosfamide and epirubicin every 14 days in women with advanced or metastatic breast cancer. ( Calvert, AH; Cantwell, BM; Chapman, F; Gumbrell, L; Lind, MJ; McCann, E; Middleton, I; Millward, MJ; Proctor, M; Simmonds, D, 1995) |
| "One hundred seventy-three eligible patients more than 1 year of age with disseminated neuroblastoma received two courses of one of the following: ifosfamide (IFOS) 2 g/m2/d for 4 days intravenously (IV) plus mesna; carboplatin (CARB) 560 mg/m2 i." | 9.07 | Phase II investigational window using carboplatin, iproplatin, ifosfamide, and epirubicin in children with untreated disseminated neuroblastoma: a Pediatric Oncology Group study. ( Berkow, RL; Buchanan, GR; Cantor, AB; Castleberry, RP; Green, AA; Hayes, FA; Joshi, V; Leventhal, B; Mahoney, DH; Smith, EI, 1994) |
| "A retrospective study to evaluate six cycles of cisplatin 40 mg/m2 on day 1 and ifosfamide 1,200 mg/m2 daily on days 1 to 4 with Mesna every four weeks as first line treatment for 29 patients with a diagnosis of uterine carcinosarcoma." | 7.83 | Efficacy and tolerability of combination cisplatin and ifosfamide chemotherapy with vaginal cuff brachytherapy in the first line treatment of uterine carcinosarcoma. ( Abu-Khalaf, MM; Azodi, M; Hatzis, C; Higgins, S; Lin, K; Ratner, E; Raza, MA; Rutherford, TJ; Santin, AD; Schwartz, PE; Silasi, DA; Wang, H, 2016) |
| "To evaluate the efficacy and safety of gemcitabine combined with ifosfamide (GI regimen)in patients with recurrent or metastatic nasopharyngeal carcinoma after failure of platinum-based chemotherapy." | 7.81 | [Efficacy and safety evaluation of gemcitabine combined with ifosfamide in patients with advanced nasopharyngeal carcinoma after failure of platinum-based chemotherapy]. ( Dong, M; Gui, L; He, X; Hu, S; Jia, B; Liu, P; Qin, Y; Yang, J; Yang, S; Zhang, C; Zhou, S, 2015) |
| "We evaluated the efficacy and tolerability of combined paclitaxel and ifosfamide in anthracycline- and docetaxel-pretreated metastatic breast cancer (MBC)." | 7.76 | Paclitaxel combined with ifosfamide in anthracycline- and docetaxel-pretreated metastatic breast cancer: activity independence of prior docetaxel resistance. ( Chang, H; Choi, HJ; Chung, HC; Kim, JH; Kim, SI; Kim, YT; Koo, JS; Moon, YW; Park, BW; Park, S; Roh, JK; Sohn, JH, 2010) |
| "Adriamycin, dacarbazine and ifosfamide are three effective chemotherapy drugs in treating progressive soft tissue sarcoma." | 7.71 | [Continuous-infusion high dose ifosfamide as salvage treatment for pre-treated soft tissue sarcoma]. ( Chen, LK; Liang, Y; Liu, JL; Teng, XY; Xu, GC; Zhou, XM, 2002) |
| "Ifosfamide, Carboplatin and Etoposide (ICE) therapy was used to treat 4 patients, 2 with refractory osteosarcoma, and one each with relapsed brain tumor and newly diagnosed brain tumor." | 7.70 | [Pilot study of relapsed osteosarcoma and brain tumor with ifosfamide, carboplatin and etoposide (ICE therapy)]. ( Agata, H; Fujimoto, T; Hamaguchi, N; Hirota, T; Iwata, A; Katano, N; Kitagawa, S; Kobayashi, S; Konno, K; Sato, T; Sawada, K; Takeuchi, M, 1998) |
| "Our objective was to assess the efficacy of a standard dose ifosfamide and doxorubicin containing regimen in the treatment of advanced soft tissue sarcomas." | 7.70 | Treatment of advanced soft tissue sarcomas with ifosfamide and doxorubicin combination chemotherapy. ( Altundağ, K; Baltali, E; Barişta, I; Celik, I; Firat, D; Güler, N; Güllü, I; Kars, A; Ozişik, Y; Tekuzman, G; Türker, A; Uner, A; Yalçin, S; Zengin, N, 2000) |
| "A total of 33 patients (median age, 44 years) with high-grade, adult soft-tissue sarcoma were treated with etoposide given at 600 mg/m2 in a 72-h continuous infusion and ifosfamide given at 1500 mg/m2 per day for 3 days every 3 weeks." | 7.69 | Treatment of advanced, high-grade soft-tissue sarcoma with ifosfamide and continuous-infusion etoposide. ( Saeter, G; Solheim, OP; Talle, K, 1995) |
| "Seven treatment-related deaths due to septicemia (three), cardiac arrhythmia (one), pneumonia (one), pneumonitis (one), and toxic epidermal necrolysis (one) were observed." | 6.73 | Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas. ( Ebeling, P; Metz, K; Moritz, T; Müller, S; Nowrousian, MR; Passon, J; Schütt, P; Seeber, S; Welt, A, 2007) |
| " Both have a dose-response relationship." | 6.68 | Phase II study of a closely spaced ifosfamide--cisplatin schedule with the addition of G-CSF in advanced non-small-cell lung cancer and malignant melanoma. ( de Wit, R; Planting, AS; Stoter, G; van der Burg, ME; Verweij, J, 1996) |
| "Ifosfamide is an alkylating agent with well-demonstrated efficacy against STS, and dose-dependent activity." | 5.37 | High-dose ifosfamide as second- or third-line chemotherapy in refractory bone and soft tissue sarcoma patients. ( Baek, KK; Chang, MH; Han, B; Lee, J; Lee, SH; Lim, T; Park, JO, 2011) |
| "In most countries, reference chemotherapy for osteosarcoma is MAP regimen (M = high-dose methotrexate, AP = doxorubicin-cisplatinum)." | 5.27 | Results of methotrexate-etoposide-ifosfamide based regimen (M-EI) in osteosarcoma patients included in the French OS2006/sarcome-09 study. ( Bompas, E; Bouvier, C; Brisse, HJ; Brugieres, L; Castex, MP; Cheurfa, N; Corradini, N; Delaye, J; Entz-Werlé, N; Gaspar, N; Gentet, JC; Italiano, A; Le Deley, MC; Lervat, C; Marec-Berard, P; Mascard, E; Occean, BV; Pacquement, H; Piperno-Neumann, S; Redini, F; Saumet, L; Schmitt, C; Tabone, MD; Verite-Goulard, C, 2018) |
| "Doxorubicin and ifosfamide are highly active drugs for the treatment of high-grade sarcomas, but little is known on the optimal management of young patients who develop such malignancies during pregnancy." | 5.16 | Doxorubicin and ifosfamide for high-grade sarcoma during pregnancy. ( Berrada, N; Bonvalot, S; Boulet, B; Cioffi, A; Domont, J; Le Cesne, A; Lokiec, F; Mir, O; Terrier, P; Trichot, C, 2012) |
| "A total of 143 patients with relapsed (n = 90), primary refractory (n = 32) and first line chemotherapy responsive (n = 21) non-Hodgkin lymphoma (NHL) and Hodgkin disease (HD) were treated with IVE (ifosphamide, etoposide and epirubicin) chemotherapy with the intent to proceed to high-dose therapy with either autologous or allogeneic transplantation, following peripheral blood stem cell mobilisation." | 5.12 | Ifosphamide, etoposide and epirubicin is an effective combined salvage and peripheral blood stem cell mobilisation regimen for transplant-eligible patients with non-Hodgkin lymphoma and Hodgkin disease. ( Bishton, MJ; Byrne, JL; Haynes, AP; Lush, RJ; Russell, NH; Shaw, BE, 2007) |
| "The relative value of increasing ifosfamide dose in combination chemotherapy for patients with soft tissue sarcoma (STS) is unclear." | 5.11 | Randomized phase II evaluation of 6 g/m2 of ifosfamide plus doxorubicin and granulocyte colony-stimulating factor (G-CSF) compared with 12 g/m2 of ifosfamide plus doxorubicin and G-CSF in the treatment of poor-prognosis soft tissue sarcoma. ( Baker, LH; Biermann, JS; Chugh, R; Leu, KM; McGinn, CJ; Sondak, VK; Taylor, JM; Worden, FP; Zalupski, MM, 2005) |
| "Our aim was to determine the efficacy of ifosfamide, mesna, and interferon alpha combination therapy in malignant mesothelioma (MM) patients." | 5.11 | Ifosfamide, mesna, and interferon-alpha2A combination chemoimmunotherapy in malignant mesothelioma: results of a single center in central anatolia. ( Altinbas, M; Coskun, HS; Ekici, E; Er, O; Eser, B; Gulmez, I; Kaplan, B; Ozesmi, M; Ozkan, M, 2004) |
| "The objectives of this trial were to estimate the response rate, progression-free survival, and overall survival of patients who received therapy with etoposide and high-dose ifosfamide, and to define the toxicity of this combination when provided with standard chemotherapy in patients with newly diagnosed metastatic osteosarcoma." | 5.10 | Phase II/III trial of etoposide and high-dose ifosfamide in newly diagnosed metastatic osteosarcoma: a pediatric oncology group trial. ( Bernstein, M; Devidas, M; Ferguson, W; Gebhardt, MC; Goorin, AM; Grier, HE; Harris, MB; Link, M; Schwartz, CL; Siegal, GP, 2002) |
| "A prospective trial to evaluate the efficacy and toxicity of ifosfamide (IFX) and vinorelbine (VNB) in patients with prior anthracycline therapy for metastatic breast cancer (MBC) was conducted." | 5.09 | Ifosfamide and vinorelbine in metastatic breast cancer in patients with prior anthracycline therapy. ( Aziz, Z; Qazi, S; Rehman, A, 1999) |
| "Twenty-four children and adolescents with metastatic sarcomas received VACIME chemotherapy, consisting of eight courses of vincristine 2 mg/m(2) on day 0; doxorubicin 20 mg/m(2)/day on days 0-3; cyclophosphamide 360 mg/m(2)/day on days 0-4; ifosfamide 1,800 mg/m(2)/day on days 0-4; mesna 2,400 mg/m(2)/day; and etoposide 100 mg/m(2)/day on days 0-4." | 5.09 | Very intensive, short-term chemotherapy for children and adolescents with metastatic sarcomas. ( Conrad, EU; Felgenhauer, J; Hawkins, D; Lindsley, K; Miser, JS; Pendergrass, T, 2000) |
| "Twenty-four patients with soft tissue or bone sarcoma who were treated with high dose ifosfamide-based chemotherapy were enrolled in this study." | 5.09 | Prospective randomized comparison of morning versus night daily single subcutaneous administration of granulocyte-macrophage-colony stimulating factor in patients with soft tissue or bone sarcoma. ( Akbulut, H; Demirkazik, A; Dinçol, D; Içli, F; Onur, H; Pamir, A; Samur, M; Sencan, O; Senler, FC; Yalçin, B, 2000) |
| "Twenty-nine patients diagnosed with recurrent neuroblastoma or PNET were treated with a combination chemotherapy regimen of cisplatin, 160 mg/m(2)/96 hours; doxorubicin, 40 mg/m(2)/96 hours; and escalated doses of etoposide and ifosfamide." | 5.09 | A phase I dose escalation of combination chemotherapy with granulocyte-macrophage-colony stimulating factor in patients with neuroblastoma. ( Fernandez, MC; Gerbing, RR; Krailo, MD; Matthay, KK, 2000) |
| " Even at the lowest dose level tested (paclitaxel 135 mg/m(2) followed by ifosfamide 1 g/m(2)/day x 4 days) grade 4 neutropenia was almost universal, despite the routine use of G-CSF." | 5.09 | Phase I trial of ifosfamide and 24-h infusional paclitaxel in pelvic malignancies: a Gynecologic Oncology Group study. ( Burger, RA; Carson, LF; Gallion, H; Lentz, SS; Markman, M; Spriggs, D, 2001) |
| "Twenty patients with locally advanced or metastatic breast cancer were treated with four cycles of ifosfamide/mesna 5 g m-2 and epirubicin 60 mg m-2 every 14 days with granulocyte colony-stimulating factor (G-CSF, Filgrastim)." | 5.08 | The use of granulocyte colony-stimulating factor to deliver four cycles of ifosfamide and epirubicin every 14 days in women with advanced or metastatic breast cancer. ( Calvert, AH; Cantwell, BM; Chapman, F; Gumbrell, L; Lind, MJ; McCann, E; Middleton, I; Millward, MJ; Proctor, M; Simmonds, D, 1995) |
| " Based on the limited clinical impact and the high incidence of rhGM-CSF-related toxicity that required growth factor discontinuation, the routine administration of rhGM-CSF to prevent neutropenia and infection after ifosfamide-based chemotherapy for GCT patients is not recommended." | 5.08 | Recombinant human granulocyte-macrophage colony-stimulating factor as an adjunct to conventional-dose ifosfamide-based chemotherapy for patients with advanced or relapsed germ cell tumors: a randomized trial. ( Bajorin, DF; Bokemeyer, C; Bosl, GJ; Demetri, GD; Einhorn, LH; Kantoff, PW; Nichols, CR; Schmoll, HJ, 1995) |
| "Adriamycin (ADM) and ifosfamide (IFO) are the two most active agents in the treatment of soft tissue sarcomas (STS) with a clear dose-response relationship." | 5.08 | High-dose ifosfamide plus adriamycin in the treatment of adult advanced soft tissue sarcomas: is it feasible? ( Aapro, MS; De Braud, F; De Pas, T; Fazio, N; Goldhirsch, A; Munzone, E; Nolè, F; Orlando, L; Zampino, MG, 1998) |
| "This two-arm, double-blind, randomized trial was conducted to determine the effects of lenograstim, a glycosylated recombinant human granulocyte colony-stimulating factor (rHu-G-CSF), on the hematologic tolerance of patients with sarcoma treated with mesna, doxorubicin, ifosfamide, and doxorubicin (MAID) chemotherapy." | 5.08 | Efficacy of lenograstim on hematologic tolerance to MAID chemotherapy in patients with advanced soft tissue sarcoma and consequences on treatment dose-intensity. ( Bonichon, F; Bui, BN; Chevallier, B; Chevreau, C; Cupissol, D; Fargeot, P; Krakowski, I; Maugard-Louboutin, C; Peny, AM; Thyss, A, 1995) |
| "The study was designed to assess the toxicity and activity of high-dose ifosfamide (HDI) administered by continuous infusion at a dose of 4 g/m2/d over 3 days every 4 weeks in adult patients with advanced soft tissue sarcomas (ASTS) pretreated with doxorubicin and/or a standard-dose ifosfamide (SDI)-containing regimen." | 5.08 | High-dose ifosfamide: circumvention of resistance to standard-dose ifosfamide in advanced soft tissue sarcomas. ( Antoine, E; Brain, E; Fontaine, F; Genin, J; Janin, N; Kayitalire, L; Le Cesne, A; Le Chevalier, T; Spielmann, M; Toussaint, C, 1995) |
| "28 patients with recurrent advanced breast cancer were treated with a salvage regimen consisting of vincristine, epirubicin and ifosfamide/mesna (VIE)." | 5.08 | Continuous infusion of vincristine, ifosfamide and epirubicin over 6 weeks in treatment-resistant advanced breast cancer. ( Gurney, H; Harnett, P; Kefford, R; Stuart-Harris, R, 1995) |
| " At the original dose of cisplatin, etoposide, and ifosfamide without G-CSF, 55% of cycles resulted in neutropenia and 38% in thrombocytopenia (dose intensity = 0." | 5.08 | Prophylactic granulocyte colony-stimulating factor allows escalation of chemotherapeutic dose intensity in advanced epithelial ovarian cancer. ( Fanning, J; Hilgers, RD, 1996) |
| "One hundred seventy-three eligible patients more than 1 year of age with disseminated neuroblastoma received two courses of one of the following: ifosfamide (IFOS) 2 g/m2/d for 4 days intravenously (IV) plus mesna; carboplatin (CARB) 560 mg/m2 i." | 5.07 | Phase II investigational window using carboplatin, iproplatin, ifosfamide, and epirubicin in children with untreated disseminated neuroblastoma: a Pediatric Oncology Group study. ( Berkow, RL; Buchanan, GR; Cantor, AB; Castleberry, RP; Green, AA; Hayes, FA; Joshi, V; Leventhal, B; Mahoney, DH; Smith, EI, 1994) |
| "A retrospective study to evaluate six cycles of cisplatin 40 mg/m2 on day 1 and ifosfamide 1,200 mg/m2 daily on days 1 to 4 with Mesna every four weeks as first line treatment for 29 patients with a diagnosis of uterine carcinosarcoma." | 3.83 | Efficacy and tolerability of combination cisplatin and ifosfamide chemotherapy with vaginal cuff brachytherapy in the first line treatment of uterine carcinosarcoma. ( Abu-Khalaf, MM; Azodi, M; Hatzis, C; Higgins, S; Lin, K; Ratner, E; Raza, MA; Rutherford, TJ; Santin, AD; Schwartz, PE; Silasi, DA; Wang, H, 2016) |
| "To evaluate the efficacy and safety of gemcitabine combined with ifosfamide (GI regimen)in patients with recurrent or metastatic nasopharyngeal carcinoma after failure of platinum-based chemotherapy." | 3.81 | [Efficacy and safety evaluation of gemcitabine combined with ifosfamide in patients with advanced nasopharyngeal carcinoma after failure of platinum-based chemotherapy]. ( Dong, M; Gui, L; He, X; Hu, S; Jia, B; Liu, P; Qin, Y; Yang, J; Yang, S; Zhang, C; Zhou, S, 2015) |
| "Patients (≥18 years old) affected by soft tissue sarcoma and treated with epirubicin and ifosfamide, underwent prophylactic treatment with G-CSF (lenograstim at 263 μg) from day 5 to day 9." | 3.79 | Lenograstim in preventing chemotherapy-induced febrile neutropenia in patients with soft tissue sarcoma. ( Badalamenti, G; Bronte, G; Fulfaro, F; Incorvaia, L; Leto, G; Maltese, G; Provenzano, S, 2013) |
| "AEs observed during 1 of 3 randomized chemotherapy regimens (vincristine, dactinomycin, and cyclophosphamide [VAC]; vincristine, dactinomycin, and ifosfamide [VAI]; or vincristine, ifosfamide, and etoposide [VIE]) in the Fourth Intergroup Rhabdomyosarcoma Study were recorded." | 3.78 | Patterns of chemotherapy-induced toxicities in younger children and adolescents with rhabdomyosarcoma: a report from the Children's Oncology Group Soft Tissue Sarcoma Committee. ( Anderson, JR; Dasgupta, R; Gupta, AA; Hawkins, DS; Indelicato, DJ; Pappo, AS; Spunt, SL, 2012) |
| "We evaluated the efficacy and tolerability of combined paclitaxel and ifosfamide in anthracycline- and docetaxel-pretreated metastatic breast cancer (MBC)." | 3.76 | Paclitaxel combined with ifosfamide in anthracycline- and docetaxel-pretreated metastatic breast cancer: activity independence of prior docetaxel resistance. ( Chang, H; Choi, HJ; Chung, HC; Kim, JH; Kim, SI; Kim, YT; Koo, JS; Moon, YW; Park, BW; Park, S; Roh, JK; Sohn, JH, 2010) |
| "Adriamycin, dacarbazine and ifosfamide are three effective chemotherapy drugs in treating progressive soft tissue sarcoma." | 3.71 | [Continuous-infusion high dose ifosfamide as salvage treatment for pre-treated soft tissue sarcoma]. ( Chen, LK; Liang, Y; Liu, JL; Teng, XY; Xu, GC; Zhou, XM, 2002) |
| "Our objective was to assess the efficacy of a standard dose ifosfamide and doxorubicin containing regimen in the treatment of advanced soft tissue sarcomas." | 3.70 | Treatment of advanced soft tissue sarcomas with ifosfamide and doxorubicin combination chemotherapy. ( Altundağ, K; Baltali, E; Barişta, I; Celik, I; Firat, D; Güler, N; Güllü, I; Kars, A; Ozişik, Y; Tekuzman, G; Türker, A; Uner, A; Yalçin, S; Zengin, N, 2000) |
| "Ifosfamide, Carboplatin and Etoposide (ICE) therapy was used to treat 4 patients, 2 with refractory osteosarcoma, and one each with relapsed brain tumor and newly diagnosed brain tumor." | 3.70 | [Pilot study of relapsed osteosarcoma and brain tumor with ifosfamide, carboplatin and etoposide (ICE therapy)]. ( Agata, H; Fujimoto, T; Hamaguchi, N; Hirota, T; Iwata, A; Katano, N; Kitagawa, S; Kobayashi, S; Konno, K; Sato, T; Sawada, K; Takeuchi, M, 1998) |
| "A total of 33 patients (median age, 44 years) with high-grade, adult soft-tissue sarcoma were treated with etoposide given at 600 mg/m2 in a 72-h continuous infusion and ifosfamide given at 1500 mg/m2 per day for 3 days every 3 weeks." | 3.69 | Treatment of advanced, high-grade soft-tissue sarcoma with ifosfamide and continuous-infusion etoposide. ( Saeter, G; Solheim, OP; Talle, K, 1995) |
| "This phase-I/phase-II study evaluated panobinostat in combination with ifosfamide, carboplatin, etoposide (P-ICE) in relapsed/refractory classical Hodgkin lymphoma." | 2.87 | Phase-I and randomized phase-II trial of panobinostat in combination with ICE (ifosfamide, carboplatin, etoposide) in relapsed or refractory classical Hodgkin lymphoma. ( Claret, L; Copeland, AR; Fanale, MA; Fayad, LE; Feng, L; Fowler, N; Hagemeister, FB; Hu, B; Nastoupil, LJ; Neelapu, S; Nieto, Y; Oki, Y; Rodriguez, MA; Romaguera, J; Samaniego, F; Turturro, F; Westin, JR; Younes, A, 2018) |
| " Major treatment-related adverse events were grade 3 or more hematologic toxicities, which included lymphopenia corresponding to dose-limiting toxicity." | 2.75 | Activity and safety of combination chemotherapy with methotrexate, ifosfamide, l-asparaginase and dexamethasone (MILD) for refractory lymphoid malignancies: a pilot study. ( Hosone, M; Isobe, Y; Katsuoka, Y; Komatsu, N; Oshimi, K; Shimizu, S; Sugimoto, K; Tsukune, Y; Yasuda, H, 2010) |
| " Sequential dose intense ifosfamide, etoposide, carboplatin +/- rituximab was more toxic and no more effective than the same drugs given in a conventional fashion." | 2.74 | Sequential high-dose ifosfamide, carboplatin and etoposide with rituximab for relapsed Hodgkin and large B-cell non-Hodgkin lymphoma: increased toxicity without improvement in progression-free survival. ( Beaven, AW; Chao, N; Gabriel, DA; Garcia, RA; Gockerman, JP; Moore, DT; Rizzieri, DA; Serody, JS; Shea, TC, 2009) |
| "Seven treatment-related deaths due to septicemia (three), cardiac arrhythmia (one), pneumonia (one), pneumonitis (one), and toxic epidermal necrolysis (one) were observed." | 2.73 | Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas. ( Ebeling, P; Metz, K; Moritz, T; Müller, S; Nowrousian, MR; Passon, J; Schütt, P; Seeber, S; Welt, A, 2007) |
| "Grade 3/4 neutropenia was observed in 21 % of patients and grade 3/4 febrile neutropenia was seen in only one patient." | 2.73 | Salvage chemotherapy with mitomycin C, ifosfamide, and cisplatin (MIC) for previously treated metastatic or recurrent esophageal squamous cell carcinoma. ( Ahn, JS; Ahn, MJ; Hwang, IG; Im, YH; Kang, WK; Lee, SC; Lim, HY; Park, BB; Park, K, 2008) |
| "Febrile neutropenia was the most frequent grade 3 or 4 nonhematologic toxicity; it occurred in 7." | 2.71 | Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma. ( Filippa, DA; Gencarelli, A; Kewalramani, T; Moskowitz, CH; Nimer, SD; Noy, A; O'Connor, O; Portlock, C; Qin, J; Straus, D; Teruya-Feldstein, J; Waxman, A; Yahalom, J; Zelenetz, AD, 2004) |
| "Grade 3-4 neutropenia was the dose limiting toxicity, observed in 36% of patients." | 2.71 | Topotecan plus ifosfamide in patients with platinum refractory advanced/metastatic non-small cell lung cancer: a phase II trial. ( Brunetti, C; Cassano, G; Colucci, G; Galetta, D; Gebbia, V; Germano, D; Giampaglia, M; Guida, M; Izzi, G; Lorusso, V; Nettis, G; Silvestris, N; Spada, M, 2005) |
| "Ifosfamide was administered at a fixed dose of 1." | 2.71 | Phase I and pharmacokinetic study of the combination of topotecan and ifosfamide administered intravenously every 3 weeks. ( Ambaum, B; Beijnen, JH; Groenewegen, G; Herben, VM; Jansen, S; Kerbusch, T; Mathôt, RA; Rosing, H; Schellens, JH; Swart, M; ten Bokkel Huinink, WW; Voest, EE, 2004) |
| "Acute renal failure and bacterial infection occurred as non-hematologic dose limiting toxicities." | 2.70 | A dose escalation study for salvage chemotherapy in patients with refractory lymphoma prior to high-dose myeloablative therapy with stem cell transplantation. ( de Magalhaes-Silverman, M; Gingrich, RD; Hayashi, M; Hohl, RJ; Lee, CK; Schlueter, A; Strauss, RG, 2002) |
| "Neutropenia was the dose limiting toxicity (G1=6%, G2=11%, G3=10%, G4=7%)." | 2.70 | Vinorelbine, ifosfamide and cisplatin as first-line treatment in patients with inoperable non-small cell lung cancer. ( Camps, C; García, R; Maestu, I; Montalar, J; Morales, S; Segura, A; Torregrosa, D; Vadell, C; Yuste, AL, 2001) |
| "Gemcitabine was administered at a dose of 800 mg/m2 on days 1 and 8 and ifosfamide at a dose of 2 g/m2 on days 1 and 8 with adequate amount of Mesna." | 2.70 | Combination chemotherapy with gemcitabine and ifosfamide as second-line treatment in metastatic urothelial cancer. A phase II trial conducted by the Hellenic Cooperative Oncology Group. ( Aravantinos, G; Bafaloukos, D; Dimopoulos, MA; Kalofonos, H; Kiamouris, C; Nicolaides, C; Pectasides, D; Visvikis, A; Xiros, N, 2001) |
| " Pharmacokinetic studies were performed on day 1 of the first course in 33 patients and repeated on day 14 in 13 patients (once-daily schedule only)." | 2.69 | Clinical effects and pharmacokinetics of the fusion protein PIXY321 in children receiving myelosuppressive chemotherapy. ( Arnold, B; Furman, WL; Garrison, L; Hanna, R; Luo, X; Marina, N; Meyer, WH; Pratt, CB; Rodman, JH; Tonda, ME, 1998) |
| "Paclitaxel was given after the first dose of ifosfamide on Day 1." | 2.69 | A Phase I trial of ifosfamide and paclitaxel with granulocyte-colony stimulating factor in the treatment of patients with refractory solid tumors. ( Berkowitz, R; Bunnell, CA; Buswell, L; Muto, M; Sheets, E; Shulman, LN; Thompson, L, 1998) |
| " We report the use of a continuous high dose infusion of ïfosfamide at a dose of 9g/m(2) over 3 days in combination with etoposide and epirubicin followed by autologous stem cell transplant with either BEAM or Melphalan/VP16 conditioning in this difficult group." | 2.69 | High dose ifosfamide in combination with etoposide and epirubicin followed by autologous stem cell transplantation in the treatment of relapsed/refractory Hodgkin's disease: a report on toxicity and efficacy. ( Angus, B; Carey, PJ; Finney, RD; Galloway, MJ; Goff, DK; Haynes, A; Jackson, GH; Lennard, AL; Leonard, RC; McQuaker, IG; Proctor, SJ; Russell, N; Taylor, PR; Windebank, K, 2000) |
| " The dosage of paclitaxel was escalated from 75 to 225 mg/m2." | 2.68 | A phase I study of ifosfamide/carboplatin/etoposide/paclitaxel in advanced lung cancer. ( Carey, RW; Elias, AD; Grossbard, ML; Jacobs, C; Jauss, S; Kwiatkowski, DJ; Lynch, TJ; Shulman, LN; Strauss, GM; Sugarbaker, DJ, 1995) |
| "Ifosfamide was therefore decreased to 1." | 2.68 | Preliminary report on a phase I study of ifosfamide and vinorelbine (navelbine) in advanced non-small cell lung cancer. ( Drinkard, LC; Golomb, HM; Hoffman, PC; Masters, GA; Samuels, BL; Vokes, EE; Watson, S, 1996) |
| "The purpose of this phase I study is to determine the maximally tolerated doses of paclitaxel and carboplatin (dosed by area under the concentration-time curve) when given at specified times in combination with 6 g/m2 ifosfamide (3 g/m2 at 8 AM on days 1 and 2) with mesna and 5 microg/kg/d filgrastim (from day 4 until the absolute neutrophil count is > 10,000/microL) every 21 days for six cycles." | 2.68 | Phase I trial of dose-escalated paclitaxel and carboplatin in combination with ifosfamide and filgrastim: preliminary results. ( Palackdharry, CS, 1996) |
| " Both have a dose-response relationship." | 2.68 | Phase II study of a closely spaced ifosfamide--cisplatin schedule with the addition of G-CSF in advanced non-small-cell lung cancer and malignant melanoma. ( de Wit, R; Planting, AS; Stoter, G; van der Burg, ME; Verweij, J, 1996) |
| "Paclitaxel starting dose was 135 mg m(-2) (day 1), with ifosfamide dose 1." | 2.68 | Paclitaxel, ifosfamide and cisplatin with granulocyte colony-stimulating factor or recombinant human interleukin 3 and granulocyte colony-stimulating factor in ovarian cancer: a feasibility study. ( Beijnen, JH; Boonstra, H; de Vries, EG; Piersma, H; van der Graaf, WT; Veldhuis, GJ; Willemse, PH, 1997) |
| "Gemcitabine was administered at a dose of 1,000 mg/m2 on days 1, 8, and 15 followed by a 1-week rest, while ifosfamide was given at a dose of 1,500 mg/m2 on day 8 and days 9 through 12." | 2.68 | A phase II trial of gemcitabine and ifosfamide in non-small cell lung cancer. ( Blatter, J; Chomy, F; Chomy, P; Drings, P; Eberhard, W; Gatzemeier, U; Khayat, D; Manegold, C; Seeber, S; Wilke, HJ, 1997) |
| "The tolerance of escalating targeted doses of carboplatin combined with ifosfamide (IFOS)/etoposide (VP-16) (ICE) was assessed in children with recurrent solid tumors." | 2.67 | Phase I study of escalating targeted doses of carboplatin combined with ifosfamide and etoposide in children with relapsed solid tumors. ( Bowman, LC; Douglass, E; Furman, W; Hudson, M; Marina, NM; Meyer, W; Rodman, J; Santana, VM; Shema, SJ; Wilimas, J, 1993) |
| "The ifosfamide was escalated in 20% increments to the maximum tolerated dosage in cohorts of three patients." | 2.67 | Ifosfamide with mesna uroprotection and etoposide in recurrent, refractory acute leukemia in childhood. A Pediatric Oncology Group Study. ( Bell, B; Bernstein, ML; Buchanan, GR; Devine, S; Dreyer, Z; Grier, H; Krischer, J; Kung, F; Land, V; Whitehead, VM, 1993) |
| "The etoposide dose was escalated, with six patients receiving 300 mg/m2 total dose (level 1), six receiving 600 mg/m2 (level 2), three receiving 900 mg/m2 (level 3), and five receiving 1,200 mg/m2 (level 4)." | 2.67 | Ifosfamide, carboplatin, and etoposide plus granulocyte-macrophage colony-stimulating factor: a phase I study with apparent activity in non-small-cell lung cancer. ( Comis, R; Haas, N; Kilpatrick, D; Krigel, RL; Langer, C; Padavic, K; Palackdharry, CS, 1994) |
| "Our study showed that the outpatient administration of interval-compressed regimen is safe and associated with acceptable adherence to this regimen." | 1.51 | Safety and Cost-effectiveness of Outpatient Administration of High-dose Chemotherapy in Children With Ewing Sarcoma. ( Alnassan, A; Elshahoubi, A; Sultan, I, 2019) |
| "Eighteen patients (35." | 1.48 | Body Mass Index as a Risk Factor for Toxicities in Patients with Advanced Soft-Tissue Sarcoma Treated with Trabectedin. ( Armento, G; Badalamenti, G; Catania, G; Incorvaia, L; Maltese, G; Napolitano, A; Santini, D; Silletta, M; Spalato Ceruso, M; Tonini, G; Valeri, S; Vincenzi, B, 2018) |
| "Ifosfamide is an alkylating agent with well-demonstrated efficacy against STS, and dose-dependent activity." | 1.37 | High-dose ifosfamide as second- or third-line chemotherapy in refractory bone and soft tissue sarcoma patients. ( Baek, KK; Chang, MH; Han, B; Lee, J; Lee, SH; Lim, T; Park, JO, 2011) |
| "Neutropenia is the most common collateral effect of chemotherapy." | 1.37 | Uncaria tomentosa stimulates the proliferation of myeloid progenitor cells. ( Alvarez-Silva, M; Asbahr, AC; Benedetti, AL; Bertol, G; Dalmora, SL; do Carmo Araújo, M; Farias, I; Farias, J; Schetinger, MR; Zimmermann, ES, 2011) |
| "Paclitaxel is a potent anticancer agent against a variety of solid cancers." | 1.33 | [Salvage chemotherapy with paclitaxel, ifosphamide and nedaplatin for relapsed or refractory germ cell cancer]. ( Kawauchi, A; Mikami, K; Miki, T; Mizutani, Y; Nakamura, T; Nakanishi, H; Nomoto, T, 2006) |
| "Seventeen patients had non-Hodgkin lymphoma (NHL) and 13 patients had Hodgkin disease (HD)." | 1.33 | IIVP salvage regimen induces high response rates in patients with relapsed lymphoma before autologous stem cell transplantation. ( Abali, H; Barista, I; Demirkazik, F; Kansu, E; Kars, A; Koc, Y; Oyan, B; Tekin, F; Tekuzman, G; Turker, A; Uner, A, 2005) |
| "We studied 19 breast cancer (BC) patients and 17 multiple myeloma (MM) patients entered in a high-dose chemotherapy (HDC) program of tandem autografting with CD34+ cell-selected PBPC." | 1.32 | Hemopoietic recovery and infectious complications in breast cancer and multiple myeloma after autologous CD34+ cell-selected peripheral blood progenitor cell transplantation. ( Amodeo, R; Anghel, G; De Rosa, L; Majolino, I; Pandolfi, A; Riccardi, M, 2004) |
| "Febrile neutropenia was observed in 5 patients (41." | 1.32 | [Paclitaxel, ifosfamide, nedaplatin (TIN) for patients with metastatic urothelial cancer]. ( Demura, T; Harabayashi, T; Ishikawa, R; Koyanagi, T; Mitsuhashi, K; Murakumo, M; Seki, H; Shinohara, N; Suzuki, S; Toyota, H, 2004) |
| "We report a case of relapsed testicular tumor complicated by neutropenic enterocolitis during high dose chemotherapy with PBSCT." | 1.30 | [A case of neutropenic enterocolitis in high dose chemotherapy with peripheral blood stem cell transplantation for relapsed testicular tumor]. ( Haga, N; Honda, K; Itoh, M; Muraki, O; Ohto, H; Tsuruya, Y; Yamaguchi, O, 1998) |
| "Records of 34 patients with ES/PNET who received the IVAD chemotherapy regimens were reviewed." | 1.30 | The use of paediatric chemotherapy protocols at full dose is both a rational and feasible treatment strategy in adults with Ewing's family tumours. ( Fisher, C; Harmer, CL; Judson, IR; Thomas, JM; Verrill, MW; Wiltshaw, E, 1997) |
| "Paclitaxel was given at a dose of 120 mg/m2 to five patients, 135 mg/m2 to five patients, 150 mg/m2 to three patients, and 175 mg/m2 to 11 patients." | 1.29 | Ifosfamide, carboplatin, etoposide, and paclitaxel chemotherapy: a dose-escalation study. ( Asbury, RF; Boros, L; Chang, AY; Garrow, GC; Hui, L, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (1.41) | 18.7374 |
| 1990's | 66 (46.48) | 18.2507 |
| 2000's | 53 (37.32) | 29.6817 |
| 2010's | 20 (14.08) | 24.3611 |
| 2020's | 1 (0.70) | 2.80 |
| Authors | Studies |
|---|---|
| Sang, W | 1 |
| Shi, M | 1 |
| Yang, J | 2 |
| Cao, J | 1 |
| Xu, L | 1 |
| Yan, D | 1 |
| Yao, M | 1 |
| Liu, H | 1 |
| Li, W | 1 |
| Zhang, B | 1 |
| Sun, K | 1 |
| Song, X | 1 |
| Sun, C | 1 |
| Jiao, J | 1 |
| Qin, Y | 2 |
| Sang, T | 1 |
| Ma, Y | 1 |
| Wu, M | 1 |
| Gao, X | 1 |
| Cheng, H | 1 |
| Yan, Z | 1 |
| Li, D | 1 |
| Sun, H | 1 |
| Zhu, F | 1 |
| Wang, Y | 2 |
| Zeng, L | 1 |
| Li, Z | 1 |
| Zheng, J | 1 |
| Xu, K | 1 |
| Hu, B | 1 |
| Younes, A | 1 |
| Westin, JR | 1 |
| Turturro, F | 1 |
| Claret, L | 1 |
| Feng, L | 1 |
| Fowler, N | 1 |
| Neelapu, S | 1 |
| Romaguera, J | 1 |
| Hagemeister, FB | 2 |
| Rodriguez, MA | 1 |
| Samaniego, F | 1 |
| Fayad, LE | 1 |
| Copeland, AR | 1 |
| Nastoupil, LJ | 1 |
| Nieto, Y | 1 |
| Fanale, MA | 1 |
| Oki, Y | 1 |
| Gaspar, N | 1 |
| Occean, BV | 1 |
| Pacquement, H | 1 |
| Bompas, E | 1 |
| Bouvier, C | 1 |
| Brisse, HJ | 1 |
| Castex, MP | 1 |
| Cheurfa, N | 1 |
| Corradini, N | 1 |
| Delaye, J | 1 |
| Entz-Werlé, N | 1 |
| Gentet, JC | 1 |
| Italiano, A | 1 |
| Lervat, C | 1 |
| Marec-Berard, P | 1 |
| Mascard, E | 1 |
| Redini, F | 1 |
| Saumet, L | 1 |
| Schmitt, C | 1 |
| Tabone, MD | 1 |
| Verite-Goulard, C | 1 |
| Le Deley, MC | 1 |
| Piperno-Neumann, S | 1 |
| Brugieres, L | 1 |
| Vincenzi, B | 1 |
| Badalamenti, G | 2 |
| Armento, G | 1 |
| Silletta, M | 1 |
| Spalato Ceruso, M | 1 |
| Catania, G | 1 |
| Napolitano, A | 1 |
| Maltese, G | 2 |
| Valeri, S | 1 |
| Incorvaia, L | 2 |
| Santini, D | 1 |
| Tonini, G | 1 |
| Elshahoubi, A | 1 |
| Alnassan, A | 1 |
| Sultan, I | 1 |
| Yin, ZM | 1 |
| Yu, AJ | 1 |
| Wu, MJ | 1 |
| Fang, J | 1 |
| Liu, LF | 1 |
| Zhu, JQ | 1 |
| Yu, H | 1 |
| Hu, S | 1 |
| He, X | 1 |
| Dong, M | 2 |
| Jia, B | 1 |
| Zhou, S | 1 |
| Yang, S | 2 |
| Zhang, C | 1 |
| Liu, P | 2 |
| Gui, L | 1 |
| Abu-Khalaf, MM | 1 |
| Raza, MA | 1 |
| Hatzis, C | 1 |
| Wang, H | 1 |
| Lin, K | 1 |
| Higgins, S | 1 |
| Ratner, E | 1 |
| Silasi, DA | 1 |
| Azodi, M | 1 |
| Rutherford, TJ | 1 |
| Santin, AD | 1 |
| Schwartz, PE | 1 |
| Kobayashi, K | 1 |
| Matsuyama, H | 1 |
| Shimizu, K | 1 |
| Fujii, N | 1 |
| Inoue, R | 1 |
| Yamamoto, Y | 1 |
| Matsumoto, H | 1 |
| Nagao, K | 1 |
| Nodomi, S | 1 |
| Umeda, K | 1 |
| Ueno, H | 1 |
| Saida, S | 1 |
| Hiramatsu, H | 1 |
| Funaki, T | 1 |
| Arakawa, Y | 1 |
| Mizowaki, T | 1 |
| Adachi, S | 1 |
| Heike, T | 1 |
| Li, XP | 1 |
| Cui, H | 1 |
| Zhou, JW | 1 |
| Wei, LH | 1 |
| Wang, JL | 1 |
| Zhao, Y | 1 |
| Wang, SJ | 1 |
| Zhu, HL | 1 |
| Dong, L | 1 |
| Zhang, H | 1 |
| Shea, TC | 1 |
| Beaven, AW | 1 |
| Moore, DT | 1 |
| Serody, JS | 1 |
| Gabriel, DA | 1 |
| Chao, N | 1 |
| Gockerman, JP | 1 |
| Garcia, RA | 1 |
| Rizzieri, DA | 1 |
| Shiu, JR | 1 |
| Romanick, M | 1 |
| Stobart, K | 1 |
| Yano, Y | 1 |
| Kodawara, T | 1 |
| Hongo, H | 1 |
| Yano, I | 1 |
| Kishi, Y | 1 |
| Takahashi, J | 1 |
| Inui, K | 1 |
| Moon, YW | 1 |
| Sohn, JH | 1 |
| Choi, HJ | 1 |
| Chang, H | 1 |
| Park, BW | 1 |
| Kim, SI | 1 |
| Park, S | 1 |
| Koo, JS | 1 |
| Kim, YT | 1 |
| Roh, JK | 2 |
| Chung, HC | 1 |
| Kim, JH | 1 |
| Tsukune, Y | 1 |
| Isobe, Y | 2 |
| Yasuda, H | 1 |
| Shimizu, S | 1 |
| Katsuoka, Y | 1 |
| Hosone, M | 1 |
| Oshimi, K | 2 |
| Komatsu, N | 1 |
| Sugimoto, K | 1 |
| Specenier, P | 1 |
| Rasschaert, M | 1 |
| Van den Brande, J | 1 |
| Dyck, J | 1 |
| Schrijvers, D | 2 |
| Huizing, MT | 1 |
| Vermorken, JB | 1 |
| Chu, P | 1 |
| Lu, CH | 1 |
| Sheng, XG | 1 |
| Zhou, CX | 1 |
| Li, DP | 1 |
| DU, XL | 1 |
| Liu, NF | 1 |
| Hong, S | 1 |
| Shin, SJ | 1 |
| Jung, M | 1 |
| Jeong, J | 1 |
| Lee, YJ | 1 |
| Shin, KH | 1 |
| Rha, SY | 1 |
| Lee, SH | 1 |
| Chang, MH | 1 |
| Baek, KK | 1 |
| Han, B | 1 |
| Lim, T | 1 |
| Lee, J | 1 |
| Park, JO | 1 |
| Gupta, AA | 1 |
| Anderson, JR | 1 |
| Pappo, AS | 2 |
| Spunt, SL | 1 |
| Dasgupta, R | 1 |
| Indelicato, DJ | 1 |
| Hawkins, DS | 1 |
| Mir, O | 1 |
| Berrada, N | 1 |
| Domont, J | 1 |
| Cioffi, A | 1 |
| Boulet, B | 1 |
| Terrier, P | 1 |
| Bonvalot, S | 1 |
| Trichot, C | 1 |
| Lokiec, F | 1 |
| Le Cesne, A | 2 |
| Farias, I | 1 |
| do Carmo Araújo, M | 1 |
| Zimmermann, ES | 1 |
| Dalmora, SL | 1 |
| Benedetti, AL | 1 |
| Alvarez-Silva, M | 1 |
| Asbahr, AC | 1 |
| Bertol, G | 1 |
| Farias, J | 1 |
| Schetinger, MR | 1 |
| Ito, Y | 1 |
| Kimura, H | 1 |
| Maeda, Y | 1 |
| Hashimoto, C | 1 |
| Ishida, F | 1 |
| Izutsu, K | 1 |
| Fukushima, N | 1 |
| Takizawa, J | 1 |
| Hasegawa, Y | 1 |
| Kobayashi, H | 2 |
| Okamura, S | 1 |
| Yamaguchi, M | 1 |
| Suzumiya, J | 1 |
| Hyo, R | 1 |
| Nakamura, S | 1 |
| Kawa, K | 1 |
| Suzuki, R | 1 |
| Provenzano, S | 1 |
| Bronte, G | 1 |
| Leto, G | 1 |
| Fulfaro, F | 1 |
| Lee, CK | 1 |
| de Magalhaes-Silverman, M | 1 |
| Hayashi, M | 1 |
| Schlueter, A | 1 |
| Strauss, RG | 1 |
| Hohl, RJ | 1 |
| Gingrich, RD | 1 |
| Chen, LK | 1 |
| Xu, GC | 1 |
| Teng, XY | 1 |
| Liang, Y | 1 |
| Liu, JL | 1 |
| Zhou, XM | 1 |
| Haddad, R | 1 |
| Posner, M | 1 |
| Arellano-Rodrigo, E | 1 |
| López-Guillermo, A | 1 |
| Bessell, EM | 1 |
| Nomdedeu, B | 1 |
| Montserrat, E | 1 |
| Graus, F | 1 |
| Kewalramani, T | 1 |
| Zelenetz, AD | 1 |
| Nimer, SD | 1 |
| Portlock, C | 1 |
| Straus, D | 1 |
| Noy, A | 1 |
| O'Connor, O | 1 |
| Filippa, DA | 1 |
| Teruya-Feldstein, J | 1 |
| Gencarelli, A | 1 |
| Qin, J | 1 |
| Waxman, A | 1 |
| Yahalom, J | 1 |
| Moskowitz, CH | 1 |
| De Rosa, L | 1 |
| Anghel, G | 1 |
| Pandolfi, A | 1 |
| Riccardi, M | 1 |
| Amodeo, R | 1 |
| Majolino, I | 1 |
| Suzuki, S | 1 |
| Shinohara, N | 1 |
| Harabayashi, T | 1 |
| Seki, H | 1 |
| Murakumo, M | 1 |
| Ishikawa, R | 1 |
| Demura, T | 1 |
| Mitsuhashi, K | 1 |
| Toyota, H | 1 |
| Koyanagi, T | 1 |
| Kerbusch, T | 1 |
| Groenewegen, G | 1 |
| Mathôt, RA | 1 |
| Herben, VM | 1 |
| ten Bokkel Huinink, WW | 1 |
| Swart, M | 1 |
| Ambaum, B | 1 |
| Rosing, H | 1 |
| Jansen, S | 1 |
| Voest, EE | 1 |
| Beijnen, JH | 2 |
| Schellens, JH | 2 |
| Altinbas, M | 1 |
| Er, O | 1 |
| Ozkan, M | 1 |
| Coskun, HS | 1 |
| Gulmez, I | 1 |
| Ekici, E | 1 |
| Kaplan, B | 1 |
| Eser, B | 1 |
| Ozesmi, M | 1 |
| Worden, FP | 1 |
| Taylor, JM | 1 |
| Biermann, JS | 1 |
| Sondak, VK | 1 |
| Leu, KM | 1 |
| Chugh, R | 1 |
| McGinn, CJ | 1 |
| Zalupski, MM | 1 |
| Baker, LH | 1 |
| Zhou, SY | 1 |
| Shi, YK | 1 |
| He, XH | 1 |
| Zhang, P | 1 |
| Huang, DZ | 1 |
| Yang, JL | 1 |
| Zhang, CG | 1 |
| Feng, FY | 1 |
| Lorigan, P | 1 |
| Woll, PJ | 2 |
| O'Brien, ME | 1 |
| Ashcroft, LF | 1 |
| Sampson, MR | 1 |
| Thatcher, N | 2 |
| Abali, H | 1 |
| Oyan, B | 1 |
| Koc, Y | 1 |
| Kars, A | 2 |
| Barista, I | 2 |
| Uner, A | 2 |
| Turker, A | 2 |
| Demirkazik, F | 1 |
| Tekin, F | 1 |
| Tekuzman, G | 2 |
| Kansu, E | 1 |
| Humphreys, BD | 1 |
| Forman, JP | 1 |
| Zandi-Nejad, K | 1 |
| Bazari, H | 1 |
| Seifter, J | 1 |
| Magee, CC | 1 |
| Chamorey, E | 1 |
| Gressin, R | 1 |
| Peyrade, F | 1 |
| Rossi, JF | 2 |
| Lepeu, G | 1 |
| Foussard, C | 1 |
| Harrousseau, JL | 1 |
| Fabbro, M | 1 |
| Richard, B | 1 |
| Delwail, V | 1 |
| Maisonneuve, H | 1 |
| Vilque, JP | 1 |
| Thyss, A | 2 |
| Lorusso, V | 1 |
| Gebbia, V | 1 |
| Spada, M | 1 |
| Guida, M | 1 |
| Cassano, G | 1 |
| Brunetti, C | 1 |
| Germano, D | 1 |
| Nettis, G | 1 |
| Izzi, G | 1 |
| Galetta, D | 1 |
| Giampaglia, M | 1 |
| Silvestris, N | 1 |
| Colucci, G | 1 |
| Bagatell, R | 1 |
| Rumcheva, P | 1 |
| London, WB | 1 |
| Cohn, SL | 1 |
| Look, AT | 1 |
| Brodeur, GM | 1 |
| Frantz, C | 1 |
| Joshi, V | 2 |
| Thorner, P | 1 |
| Rao, PV | 1 |
| Castleberry, R | 1 |
| Bowman, LC | 4 |
| Nomoto, T | 1 |
| Mizutani, Y | 1 |
| Mikami, K | 1 |
| Nakamura, T | 1 |
| Nakanishi, H | 1 |
| Kawauchi, A | 1 |
| Miki, T | 1 |
| Li, EX | 1 |
| Zhang, YT | 1 |
| Shang, JT | 1 |
| Xu, Z | 1 |
| Geng, Y | 1 |
| Li, SM | 1 |
| Shi, F | 1 |
| Wu, YY | 1 |
| Su, Y | 1 |
| Bishton, MJ | 1 |
| Lush, RJ | 1 |
| Byrne, JL | 1 |
| Russell, NH | 1 |
| Shaw, BE | 1 |
| Haynes, AP | 1 |
| Schütt, P | 1 |
| Passon, J | 1 |
| Ebeling, P | 1 |
| Welt, A | 1 |
| Müller, S | 1 |
| Metz, K | 1 |
| Moritz, T | 1 |
| Seeber, S | 2 |
| Nowrousian, MR | 1 |
| Todisco, E | 1 |
| Castagna, L | 1 |
| Sarina, B | 1 |
| Mazza, R | 1 |
| Magagnoli, M | 1 |
| Balzarotti, M | 1 |
| Nozza, A | 1 |
| Siracusano, L | 1 |
| Timofeeva, I | 1 |
| Anastasia, A | 1 |
| Demarco, M | 1 |
| Santoro, A | 2 |
| Park, BB | 1 |
| Im, YH | 1 |
| Hwang, IG | 1 |
| Lee, SC | 1 |
| Ahn, JS | 1 |
| Ahn, MJ | 1 |
| Lim, HY | 1 |
| Kang, WK | 1 |
| Park, K | 1 |
| Valdivieso, M | 1 |
| Bodey, GP | 2 |
| Benjamin, RS | 1 |
| Barkley, HT | 1 |
| Freeman, MB | 1 |
| Ertel, M | 1 |
| Smith, TL | 1 |
| Mountain, CF | 1 |
| Cabanillas, F | 1 |
| Freireich, EJ | 1 |
| Dinçol, D | 2 |
| Içli, F | 2 |
| Karaoğuz, H | 1 |
| Cay, F | 1 |
| Arican, A | 1 |
| Demirkazik, A | 2 |
| Akbulut, H | 2 |
| Di Leo, A | 1 |
| Bajetta, E | 1 |
| Nolè, F | 2 |
| Biganzoli, L | 1 |
| Ferrari, L | 1 |
| Oriana, S | 1 |
| Riboldi, G | 1 |
| Bohm, S | 1 |
| Spatti, G | 1 |
| Raspagliesi, F | 1 |
| Carlson, JW | 1 |
| Fowler, JM | 1 |
| Saltzman, AK | 1 |
| Carter, JR | 1 |
| Chen, MD | 1 |
| Mitchell, SK | 1 |
| Dunn, D | 1 |
| Carson, LF | 2 |
| Adcock, LL | 1 |
| Twiggs, LB | 1 |
| Lind, MJ | 1 |
| Gumbrell, L | 1 |
| Cantwell, BM | 1 |
| Millward, MJ | 1 |
| Simmonds, D | 1 |
| Proctor, M | 1 |
| Chapman, F | 1 |
| McCann, E | 1 |
| Middleton, I | 1 |
| Calvert, AH | 1 |
| Hodgetts, J | 1 |
| Lomax, L | 1 |
| Bildet, F | 1 |
| Cour-Chabernaud, V | 1 |
| Beyer, J | 2 |
| Schwella, N | 1 |
| Zingsem, J | 1 |
| Strohscheer, I | 1 |
| Schwaner, I | 1 |
| Oettle, H | 1 |
| Serke, S | 1 |
| Huhn, D | 1 |
| Stieger, W | 1 |
| Saeter, G | 1 |
| Talle, K | 1 |
| Solheim, OP | 1 |
| Toma, S | 1 |
| Palumbo, R | 1 |
| Comandone, A | 1 |
| Oliva, C | 1 |
| Vincenti, M | 1 |
| Bumma, C | 1 |
| Rosso, R | 1 |
| Antoine, E | 1 |
| Spielmann, M | 1 |
| Le Chevalier, T | 2 |
| Brain, E | 2 |
| Toussaint, C | 1 |
| Janin, N | 1 |
| Kayitalire, L | 1 |
| Fontaine, F | 1 |
| Genin, J | 1 |
| Crawford, J | 1 |
| George, M | 1 |
| Strauss, GM | 1 |
| Lynch, TJ | 1 |
| Elias, AD | 1 |
| Jacobs, C | 1 |
| Kwiatkowski, DJ | 1 |
| Shulman, LN | 2 |
| Carey, RW | 1 |
| Grossbard, ML | 1 |
| Jauss, S | 1 |
| Sugarbaker, DJ | 1 |
| Bui, BN | 1 |
| Chevallier, B | 1 |
| Chevreau, C | 1 |
| Krakowski, I | 1 |
| Peny, AM | 1 |
| Maugard-Louboutin, C | 1 |
| Cupissol, D | 1 |
| Fargeot, P | 1 |
| Bonichon, F | 1 |
| Cairo, MS | 2 |
| Bajorin, DF | 1 |
| Nichols, CR | 1 |
| Schmoll, HJ | 2 |
| Kantoff, PW | 1 |
| Bokemeyer, C | 2 |
| Demetri, GD | 1 |
| Einhorn, LH | 1 |
| Bosl, GJ | 1 |
| Castleberry, RP | 1 |
| Cantor, AB | 1 |
| Green, AA | 1 |
| Berkow, RL | 1 |
| Buchanan, GR | 2 |
| Leventhal, B | 1 |
| Mahoney, DH | 1 |
| Smith, EI | 1 |
| Hayes, FA | 1 |
| Marina, NM | 2 |
| Shema, SJ | 2 |
| Rodman, J | 2 |
| Douglass, EC | 1 |
| Furman, WL | 3 |
| Pappo, A | 1 |
| Santana, VM | 2 |
| Hudson, M | 2 |
| Meyer, WH | 2 |
| Krigel, RL | 1 |
| Palackdharry, CS | 2 |
| Padavic, K | 1 |
| Haas, N | 1 |
| Kilpatrick, D | 1 |
| Langer, C | 1 |
| Comis, R | 1 |
| Metzner, B | 1 |
| Illiger, HJ | 1 |
| Kneba, M | 1 |
| Ostermann, H | 1 |
| Kynast, B | 1 |
| Räth, U | 1 |
| Poliwoda, H | 1 |
| Bernstein, ML | 1 |
| Whitehead, VM | 1 |
| Devine, S | 1 |
| Grier, H | 1 |
| Kung, F | 1 |
| Krischer, J | 1 |
| Dreyer, Z | 1 |
| Bell, B | 1 |
| Land, V | 1 |
| Graziano, SL | 1 |
| Herndon, JE | 1 |
| Richards, F | 1 |
| DiFino, S | 1 |
| Modeas, C | 1 |
| Duggan, DB | 1 |
| Green, MR | 1 |
| Douglass, E | 1 |
| Furman, W | 1 |
| Wilimas, J | 1 |
| Meyer, W | 1 |
| Gurney, H | 1 |
| Harnett, P | 1 |
| Stuart-Harris, R | 1 |
| Kefford, R | 1 |
| Michelotti, A | 1 |
| Romanini, A | 1 |
| Giannessi, P | 1 |
| Bengala, C | 1 |
| Conte, P | 1 |
| Welte, K | 1 |
| Reiter, A | 1 |
| Mempel, K | 1 |
| Pfetsch, M | 1 |
| Schwab, G | 1 |
| Schrappe, M | 1 |
| Riehm, H | 1 |
| Masters, GA | 2 |
| Hoffman, PC | 2 |
| Drinkard, LC | 2 |
| Watson, S | 1 |
| Samuels, BL | 2 |
| Golomb, HM | 2 |
| Vokes, EE | 2 |
| Magrath, I | 1 |
| Adde, M | 1 |
| Shad, A | 1 |
| Venzon, D | 1 |
| Seibel, N | 1 |
| Gootenberg, J | 1 |
| Neely, J | 1 |
| Arndt, C | 1 |
| Nieder, M | 1 |
| Jaffe, E | 1 |
| Wittes, RA | 1 |
| Horak, ID | 1 |
| Lee, PK | 1 |
| Dover, JS | 1 |
| Wong, ET | 1 |
| Portlock, CS | 1 |
| O'Brien, JP | 1 |
| DeAngelis, LM | 1 |
| Krauss, SA | 1 |
| Chang, AY | 1 |
| Boros, L | 1 |
| Garrow, GC | 1 |
| Asbury, RF | 1 |
| Hui, L | 1 |
| Stein, ME | 1 |
| Ruff, P | 1 |
| Weaving, A | 1 |
| Fried, J | 1 |
| Bezwoda, WR | 1 |
| Lokich, J | 1 |
| Anderson, N | 1 |
| Moore, C | 1 |
| Bern, M | 1 |
| Coco, F | 1 |
| Dow, E | 1 |
| Wexler, LH | 1 |
| DeLaney, TF | 1 |
| Tsokos, M | 1 |
| Avila, N | 1 |
| Steinberg, SM | 1 |
| Weaver-McClure, L | 1 |
| Jacobson, J | 1 |
| Jarosinski, P | 1 |
| Hijazi, YM | 1 |
| Balis, FM | 1 |
| Horowitz, ME | 1 |
| Trillet-Lenoir, V | 1 |
| Soler, P | 1 |
| Arpin, D | 1 |
| Bohas, C | 1 |
| Riou, R | 1 |
| Court-Fortune, I | 1 |
| Ecochard, D | 1 |
| Perol, M | 1 |
| Cordier, JF | 1 |
| Fanning, J | 1 |
| Hilgers, RD | 1 |
| Shepherd, FA | 3 |
| Latreille, J | 3 |
| Paul, K | 2 |
| Eisenhauer, E | 1 |
| Planting, AS | 2 |
| de Wit, R | 1 |
| van der Burg, ME | 1 |
| Stoter, G | 1 |
| Verweij, J | 2 |
| Veldhuis, GJ | 1 |
| Willemse, PH | 1 |
| Boonstra, H | 1 |
| Piersma, H | 1 |
| van der Graaf, WT | 1 |
| de Vries, EG | 1 |
| Katschinski, DM | 1 |
| Wiedemann, GJ | 1 |
| Mentzel, M | 1 |
| Mulkerin, DL | 1 |
| Touhidi, R | 1 |
| Robins, HI | 1 |
| Chen, YM | 2 |
| Wu, MF | 1 |
| Perng, RP | 2 |
| Chou, CM | 1 |
| Yang, KY | 1 |
| Lin, WC | 2 |
| Tsai, CM | 2 |
| Liu, JM | 1 |
| Whang-Peng, J | 2 |
| Gatzemeier, U | 1 |
| Manegold, C | 1 |
| Eberhard, W | 1 |
| Wilke, HJ | 1 |
| Chomy, F | 1 |
| Chomy, P | 1 |
| Khayat, D | 1 |
| Blatter, J | 1 |
| Drings, P | 1 |
| Fridrik, MA | 1 |
| Greil, R | 1 |
| Hausmaninger, H | 1 |
| Krieger, O | 1 |
| Oppitz, P | 1 |
| Stöger, M | 1 |
| Klocker, J | 1 |
| Neubauer, M | 1 |
| Helm, W | 1 |
| Pont, J | 1 |
| Fazeny, B | 1 |
| Hudec, M | 1 |
| Simonitsch, I | 1 |
| Radaszkiewicz, T | 1 |
| Verrill, MW | 1 |
| Judson, IR | 1 |
| Wiltshaw, E | 1 |
| Thomas, JM | 1 |
| Harmer, CL | 1 |
| Fisher, C | 1 |
| Rodman, JH | 1 |
| Tonda, ME | 1 |
| Luo, X | 1 |
| Arnold, B | 1 |
| Marina, N | 1 |
| Garrison, L | 1 |
| Hanna, R | 1 |
| Pratt, CB | 2 |
| Glisson, B | 3 |
| Lee, JS | 2 |
| Palmer, J | 1 |
| Fossella, F | 2 |
| Shin, DM | 2 |
| Murphy, WK | 2 |
| Perez-Soler, R | 2 |
| Hong, WK | 1 |
| Bunnell, CA | 1 |
| Thompson, L | 1 |
| Buswell, L | 1 |
| Berkowitz, R | 1 |
| Muto, M | 1 |
| Sheets, E | 1 |
| Komaki, R | 2 |
| Kurie, J | 1 |
| Schea, R | 1 |
| Vadhan-Raj, S | 1 |
| Pronk, LC | 1 |
| de Bruijn, EA | 1 |
| Locci-Tonelli, D | 1 |
| Groult, V | 1 |
| van Oosterom, AT | 1 |
| Walter, AW | 1 |
| Shearer, PD | 1 |
| Greenwald, CA | 1 |
| Rao, BN | 1 |
| Gajjar, A | 1 |
| Jenkins, JJ | 1 |
| Hirota, T | 1 |
| Takeuchi, M | 1 |
| Iwata, A | 1 |
| Kitagawa, S | 1 |
| Sato, T | 1 |
| Konno, K | 1 |
| Sawada, K | 1 |
| Kobayashi, S | 1 |
| Hamaguchi, N | 1 |
| Agata, H | 1 |
| Katano, N | 1 |
| Fujimoto, T | 1 |
| Theis, JG | 2 |
| Chan, HS | 2 |
| Greenberg, ML | 2 |
| Malkin, D | 2 |
| Karaskov, V | 2 |
| Moncica, I | 2 |
| Koren, G | 2 |
| Doyle, J | 2 |
| Pronzato, P | 2 |
| Losardo, P | 1 |
| Pensa, F | 2 |
| Tognoni, A | 2 |
| De Pas, T | 2 |
| De Braud, F | 1 |
| Orlando, L | 1 |
| Munzone, E | 1 |
| Zampino, MG | 1 |
| Fazio, N | 1 |
| Aapro, MS | 1 |
| Goldhirsch, A | 1 |
| Bonfante, V | 1 |
| Viviani, S | 1 |
| Devizzi, L | 1 |
| Di Russo, A | 1 |
| Zanini, M | 1 |
| Soncini, F | 1 |
| Soto Parra, H | 1 |
| Valagussa, P | 1 |
| Bonadonna, G | 1 |
| Muraki, O | 1 |
| Itoh, M | 1 |
| Haga, N | 1 |
| Tsuruya, Y | 1 |
| Honda, K | 1 |
| Yamaguchi, O | 1 |
| Ohto, H | 1 |
| Lehrich, RW | 1 |
| Moll, S | 1 |
| Luft, FC | 1 |
| Philip, PA | 1 |
| Rea, D | 1 |
| Mitchell, K | 1 |
| Carmichael, J | 1 |
| Harris, AL | 1 |
| Talbot, DC | 1 |
| van de Velde, H | 1 |
| Bosquée, L | 1 |
| Weynants, P | 1 |
| Canon, JL | 1 |
| Rosier, JF | 1 |
| Humblet, Y | 1 |
| Soulié, P | 1 |
| Garrino, C | 1 |
| Bensmaïne, MA | 1 |
| Bekradda, M | 1 |
| Di Palma, M | 1 |
| Goupil, A | 1 |
| Misset, JL | 1 |
| Cvitkovic, E | 1 |
| Aziz, Z | 1 |
| Rehman, A | 1 |
| Qazi, S | 1 |
| Felgenhauer, J | 1 |
| Hawkins, D | 1 |
| Pendergrass, T | 1 |
| Lindsley, K | 1 |
| Conrad, EU | 1 |
| Miser, JS | 2 |
| Kosmas, C | 1 |
| Tsavaris, NB | 1 |
| Polyzos, A | 1 |
| Malamos, NA | 1 |
| Katsikas, M | 1 |
| Antonopoulos, MJ | 1 |
| Yalçin, S | 1 |
| Güllü, I | 1 |
| Güler, N | 1 |
| Ozişik, Y | 1 |
| Celik, I | 1 |
| Altundağ, K | 1 |
| Zengin, N | 1 |
| Baltali, E | 1 |
| Firat, D | 1 |
| Samur, M | 1 |
| Pamir, A | 1 |
| Sencan, O | 1 |
| Yalçin, B | 1 |
| Onur, H | 1 |
| Senler, FC | 1 |
| Fernandez, MC | 1 |
| Krailo, MD | 2 |
| Gerbing, RR | 1 |
| Matthay, KK | 1 |
| Boni, C | 1 |
| Bisagni, G | 1 |
| Savoldi, L | 1 |
| Moretti, G | 1 |
| Rondini, E | 1 |
| Sassi, M | 1 |
| Zadro, A | 1 |
| Franciosi, V | 1 |
| Pazzola, A | 1 |
| Vignoli, R | 1 |
| Banzi, MC | 1 |
| Pajetta, V | 1 |
| Scott, C | 1 |
| Movsas, B | 1 |
| Wagner, H | 1 |
| Jackson, GH | 1 |
| Angus, B | 1 |
| Carey, PJ | 1 |
| Finney, RD | 1 |
| Galloway, MJ | 1 |
| Goff, DK | 1 |
| Haynes, A | 1 |
| Lennard, AL | 1 |
| Leonard, RC | 1 |
| McQuaker, IG | 1 |
| Proctor, SJ | 1 |
| Russell, N | 1 |
| Windebank, K | 1 |
| Taylor, PR | 1 |
| Cesaro, S | 1 |
| Chinello, P | 1 |
| Rossi, L | 1 |
| Zanesco, L | 1 |
| Wu, HW | 1 |
| Johnson, PW | 1 |
| Muers, MF | 1 |
| Peake, MD | 1 |
| Poulter, KM | 1 |
| Gurney, EM | 1 |
| Napp, VV | 1 |
| Hepburn, PM | 1 |
| Brown, JM | 1 |
| Shen, V | 1 |
| Bauer, M | 1 |
| Sato, JK | 1 |
| Blatt, J | 1 |
| Blazar, BR | 1 |
| Frierdich, S | 1 |
| Liu-Mares, W | 1 |
| Reaman, GH | 1 |
| Fleming, GF | 1 |
| Waggoner, SE | 1 |
| Rotmensch, J | 1 |
| Langhauser, C | 1 |
| Markman, M | 1 |
| Spriggs, D | 1 |
| Burger, RA | 1 |
| Lentz, SS | 1 |
| Gallion, H | 1 |
| Thurnher, D | 1 |
| Kornfehl, J | 1 |
| Burian, M | 1 |
| Gedlicka, C | 1 |
| Selzer, E | 1 |
| Quint, C | 1 |
| Neuchrist, C | 1 |
| Kornek, GV | 1 |
| Vaira, F | 1 |
| Vigani, A | 1 |
| Bancalari, L | 1 |
| Fiasella, L | 1 |
| Maggiani, R | 1 |
| Canessa, P | 1 |
| Noël, G | 1 |
| Mazeron, JJ | 1 |
| Fulda, S | 1 |
| Fichtner, I | 1 |
| Hero, B | 1 |
| Berthold, F | 1 |
| García-Rayo, S | 1 |
| Pérez-Calvo, J | 1 |
| Martín-Algarra, S | 1 |
| Martínez-Monge, R | 1 |
| Fernández-Hidalgo, O | 1 |
| Subirá, L | 1 |
| Martínez-Aguillo, M | 1 |
| Rebollo, J | 1 |
| Azinovic, I | 1 |
| Brugarolas, A | 1 |
| Lee, EJ | 1 |
| Petroni, GR | 1 |
| Schiffer, CA | 1 |
| Freter, CE | 1 |
| Johnson, JL | 1 |
| Barcos, M | 1 |
| Frizzera, G | 1 |
| Bloomfield, CD | 1 |
| Peterson, BA | 1 |
| Montalar, J | 1 |
| Morales, S | 1 |
| Maestu, I | 1 |
| Camps, C | 1 |
| Vadell, C | 1 |
| García, R | 1 |
| Yuste, AL | 1 |
| Torregrosa, D | 1 |
| Segura, A | 1 |
| Pectasides, D | 1 |
| Aravantinos, G | 1 |
| Kalofonos, H | 1 |
| Kiamouris, C | 1 |
| Bafaloukos, D | 1 |
| Xiros, N | 1 |
| Nicolaides, C | 1 |
| Visvikis, A | 1 |
| Dimopoulos, MA | 1 |
| Goorin, AM | 1 |
| Harris, MB | 1 |
| Bernstein, M | 1 |
| Ferguson, W | 1 |
| Devidas, M | 1 |
| Siegal, GP | 1 |
| Gebhardt, MC | 1 |
| Schwartz, CL | 1 |
| Link, M | 1 |
| Grier, HE | 1 |
| González-Martín, A | 1 |
| Crespo, C | 1 |
| García-López, JL | 1 |
| Pedraza, M | 1 |
| Garrido, P | 1 |
| Lastra, E | 1 |
| Moyano, A | 1 |
| Evans, WK | 2 |
| Goss, PE | 2 |
| Logan, D | 2 |
| Maroun, J | 2 |
| Stewart, D | 2 |
| Warner, E | 2 |
| Ohnoshi, T | 1 |
| Ueoka, H | 1 |
| Kodani, T | 1 |
| Kamei, H | 1 |
| Kimura, I | 1 |
| Smith, IE | 1 |
| Perren, TJ | 1 |
| Ashley, SA | 1 |
| Woodiwiss, J | 1 |
| Forgeson, GV | 1 |
| Yarnold, JR | 1 |
| Ford, HT | 1 |
| Pujol, JL | 1 |
| Daurès, JP | 1 |
| Rouanet, P | 1 |
| Douillard, JY | 1 |
| Dubois, JB | 1 |
| Arriagada, R | 1 |
| Mary, H | 1 |
| Godard, P | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Sequential Infusion of Anti-CD19 and Anti-CD20 Chimeric Antigen Receptor(CAR) T Cells Against Relapsed and Refractory B-cell Lymphoma[NCT03207178] | Phase 1/Phase 2 | 20 participants (Anticipated) | Interventional | 2017-03-01 | Recruiting | ||
| Clinical Efficacy and Safety of IBER Salvage Treatment Followed by Ibrutinib Maintenance for Transplant-ineligible Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma (PCNSL): a Multicenter, Single-arm, Prospective Phase II Study[NCT04066920] | Phase 2 | 30 participants (Anticipated) | Interventional | 2019-10-01 | Not yet recruiting | ||
| Randomized Study of ICE Plus RITUXIMAB Versus DHAP Plus Rituximab in Previously Treated Patients With Diffuse Large B-cell Lymphoma, Followed by Randomized Maintenance With Rituximab[NCT00137995] | Phase 3 | 481 participants (Actual) | Interventional | 2003-06-30 | Completed | ||
| Phase II Trial Investigating Tailoring First-Line Therapy For Advanced Stage Diffuse Large B-Cell Non-Hodgkin's Lymphoma Based on Mid-Treatment Positron Emission Tomography (PET) Scan Results[NCT00324467] | Phase 2 | 150 participants (Actual) | Interventional | 2006-08-31 | Active, not recruiting | ||
| Cytoreduction and Stem Cell Mobilization With Rituximab and ICE for Patients With Refractory or Relapsed CD20+ B-Cell IGL Eligible for ASCT: The RICE Protocol[NCT00005631] | Phase 2 | 0 participants | Interventional | 1999-11-30 | Completed | ||
| Burkimab:Study Multicenter of Optimization of the Treatment of LLA-B and the Burkitt's Lymphoma in Adult Patients (From 15 Years Old)[NCT00388193] | Phase 2 | 20 participants (Anticipated) | Interventional | 2006-08-31 | Completed | ||
| HIGH INTENSITY, BRIEF DURATION CHEMOTHERAPY FOR DIFFUSE SMALL NONCLEAVED CELL LYMPHOMA AND THE L-3 SUBTYPE OF ALL: A PILOT STUDY OF A MULTIDRUG REGIMEN[NCT00002494] | Phase 2 | 134 participants (Actual) | Interventional | 1992-05-31 | Completed | ||
| Treatment of Mature B-ALL and Burkitt Lymphoma (BL) in Adult Patients. BURKIMAB-14.[NCT05049473] | Phase 2 | 100 participants (Anticipated) | Interventional | 2014-01-31 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for ifosfamide and Neutropenia
| Article | Year |
|---|---|
The role of hematopoietic growth factors in support of ifosfamide/carboplatin/etoposide chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinica | 1995 |
The use of ifosfamide, carboplatin, and etoposide in children with solid tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Etoposide; Humans; Ifosfamide; L | 1995 |
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid | 2001 |
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid | 2001 |
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid | 2001 |
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid | 2001 |
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid | 2001 |
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid | 2001 |
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid | 2001 |
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid | 2001 |
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid | 2001 |
94 trials available for ifosfamide and Neutropenia
| Article | Year |
|---|---|
Phase II trial of co-administration of CD19- and CD20-targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma.
Topics: Adult; Aged; Anemia; Antigens, CD19; Antigens, CD20; Antineoplastic Agents; B-Lymphocytes; CD4-CD8 R | 2020 |
Phase-I and randomized phase-II trial of panobinostat in combination with ICE (ifosfamide, carboplatin, etoposide) in relapsed or refractory classical Hodgkin lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carboplatin; Drug Administ | 2018 |
Results of methotrexate-etoposide-ifosfamide based regimen (M-EI) in osteosarcoma patients included in the French OS2006/sarcome-09 study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Pre | 2018 |
[Efficacy and tolerability of the combination of oxaliplatin, ifosfamide, and epirubicin in treatment of recurrent or platinum-resistant ovarian epithelial cancer patients].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; | 2008 |
Sequential high-dose ifosfamide, carboplatin and etoposide with rituximab for relapsed Hodgkin and large B-cell non-Hodgkin lymphoma: increased toxicity without improvement in progression-free survival.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Etoposide; Feasibility Stu | 2009 |
Activity and safety of combination chemotherapy with methotrexate, ifosfamide, l-asparaginase and dexamethasone (MILD) for refractory lymphoid malignancies: a pilot study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Female; Hematologic Neopl | 2010 |
Docetaxel, ifosfamide and cisplatin in solid tumour treatment: a phase I study.
Topics: Adult; Aged; Antibiotic Prophylaxis; Antineoplastic Combined Chemotherapy Protocols; Brain Injuries; | 2010 |
[Gemcitabine based combination chemotherapy, a new salvage regimen for recurrent platinum resistant epithelial ovarian cancer].
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Resistanc | 2010 |
Doxorubicin and ifosfamide for high-grade sarcoma during pregnancy.
Topics: Adult; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug Administration Sc | 2012 |
Pretreatment EBV-DNA copy number is predictive of response and toxicities to SMILE chemotherapy for extranodal NK/T-cell lymphoma, nasal type.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; DNA, Viral; E | 2012 |
A dose escalation study for salvage chemotherapy in patients with refractory lymphoma prior to high-dose myeloablative therapy with stem cell transplantation.
Topics: Acute Kidney Injury; Adult; Antineoplastic Combined Chemotherapy Protocols; Bacterial Infections; Cy | 2002 |
Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, C | 2004 |
Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, C | 2004 |
Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, C | 2004 |
Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, C | 2004 |
Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, C | 2004 |
Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, C | 2004 |
Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, C | 2004 |
Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, C | 2004 |
Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, C | 2004 |
Phase I and pharmacokinetic study of the combination of topotecan and ifosfamide administered intravenously every 3 weeks.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; D | 2004 |
Ifosfamide, mesna, and interferon-alpha2A combination chemoimmunotherapy in malignant mesothelioma: results of a single center in central anatolia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Female; Humans; If | 2004 |
Randomized phase II evaluation of 6 g/m2 of ifosfamide plus doxorubicin and granulocyte colony-stimulating factor (G-CSF) compared with 12 g/m2 of ifosfamide plus doxorubicin and G-CSF in the treatment of poor-prognosis soft tissue sarcoma.
Topics: Adolescent; Adult; Aged; Anemia; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Ant | 2005 |
Randomized phase III trial of dose-dense chemotherapy supported by whole-blood hematopoietic progenitors in better-prognosis small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Dos | 2005 |
Prospective randomized study comparing MEMID with a chop-like regimen in elderly patients with aggressive non-Hodgkin's lymphoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Disease-Free | 2005 |
Topotecan plus ifosfamide in patients with platinum refractory advanced/metastatic non-small cell lung cancer: a phase II trial.
Topics: Adult; Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small- | 2005 |
Outcomes of children with intermediate-risk neuroblastoma after treatment stratified by MYCN status and tumor cell ploidy.
Topics: Abdominal Neoplasms; Adolescent; Adrenal Gland Neoplasms; Antineoplastic Combined Chemotherapy Proto | 2005 |
Ifosphamide, etoposide and epirubicin is an effective combined salvage and peripheral blood stem cell mobilisation regimen for transplant-eligible patients with non-Hodgkin lymphoma and Hodgkin disease.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Epirubicin; Etoposide; Female; Hematopo | 2007 |
Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Combined Modality Thera | 2007 |
CD34+ dose-driven administration of granulocyte colony-stimulating factor after high-dose chemotherapy in lymphoma patients.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Muri | 2007 |
Salvage chemotherapy with mitomycin C, ifosfamide, and cisplatin (MIC) for previously treated metastatic or recurrent esophageal squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Di | 2008 |
Role of intravenous hyperalimentation as an adjunct to intensive chemotherapy for small cell bronchogenic carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Bon | 1981 |
The intramuscular administration of granulocyte colony-stimulating factor as an adjunct to chemotherapy in pretreated ovarian cancer patients: an Italian Trials in Medical Oncology (ITMO) Group pilot study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Female; Granulocyte Colony-S | 1994 |
The use of granulocyte colony-stimulating factor to deliver four cycles of ifosfamide and epirubicin every 14 days in women with advanced or metastatic breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration Schedul | 1995 |
Can cytotoxic dose-intensity be increased by using granulocyte colony-stimulating factor? A randomized controlled trial of lenograstim in small-cell lung cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Sma | 1995 |
Hematopoietic rescue after high-dose chemotherapy using autologous peripheral-blood progenitor cells or bone marrow: a randomized comparison.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carb | 1995 |
Ambulatory 4-day continuous-infusion schedule of high-dose ifosfamide with mesna uroprotection and granulocyte colony-stimulating factor in advanced solid tumours: a phase I study.
Topics: Adult; Aged; Ambulatory Care; Female; Granulocyte Colony-Stimulating Factor; Humans; Ifosfamide; Imm | 1995 |
High-dose ifosfamide: circumvention of resistance to standard-dose ifosfamide in advanced soft tissue sarcomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Diseases; Dacarbazine; Doxorubici | 1995 |
A phase I study of ifosfamide/carboplatin/etoposide/paclitaxel in advanced lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carboplatin; Carcinoma, No | 1995 |
Efficacy of lenograstim on hematologic tolerance to MAID chemotherapy in patients with advanced soft tissue sarcoma and consequences on treatment dose-intensity.
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Double-Blind Met | 1995 |
Recombinant human granulocyte-macrophage colony-stimulating factor as an adjunct to conventional-dose ifosfamide-based chemotherapy for patients with advanced or relapsed germ cell tumors: a randomized trial.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Etoposide; Germinoma; | 1995 |
Phase II investigational window using carboplatin, iproplatin, ifosfamide, and epirubicin in children with untreated disseminated neuroblastoma: a Pediatric Oncology Group study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Child, Presch | 1994 |
Ifosfamide, carboplatin, and etoposide plus granulocyte-macrophage colony-stimulating factor: a phase I study with apparent activity in non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell | 1994 |
Comparison of 5 vs 10 micrograms/kg per day of GM-CSF following dose-intensified chemotherapy with cisplatin, etoposide, and ifosfamide in patients with advanced testicular cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Etoposide; Granulocyte-Macrophage Colony- | 1993 |
Ifosfamide with mesna uroprotection and etoposide in recurrent, refractory acute leukemia in childhood. A Pediatric Oncology Group Study.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Marrow Transplantat | 1993 |
A phase I trial of ifosfamide, mesna, and cisplatin in advanced non-small cell lung cancer. A cancer and leukemia group B study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1993 |
Phase I study of escalating targeted doses of carboplatin combined with ifosfamide and etoposide in children with relapsed solid tumors.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Child, Presch | 1993 |
Continuous infusion of vincristine, ifosfamide and epirubicin over 6 weeks in treatment-resistant advanced breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Epirubicin; Female; Hemoglo | 1995 |
Accelerated epirubicin-ifosfamide-dacarbazine regimen in patients with adult soft tissue sarcomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Dose-Response | 1996 |
A randomized phase-III study of the efficacy of granulocyte colony-stimulating factor in children with high-risk acute lymphoblastic leukemia. Berlin-Frankfurt-Münster Study Group.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; C | 1996 |
Preliminary report on a phase I study of ifosfamide and vinorelbine (navelbine) in advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Co | 1996 |
Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen.
Topics: Adolescent; Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Presch | 1996 |
Chemosensitive epidural spinal cord disease in non-Hodgkins lymphoma.
Topics: Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Dox | 1996 |
Ifosfamide-based combination chemotherapy in advanced non-small cell lung cancer: two phase I studies.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Co | 1996 |
Phase I trial of dose-escalated paclitaxel and carboplatin in combination with ifosfamide and filgrastim: preliminary results.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytog | 1996 |
A phase II study of cisplatin/ifosfamide in recurrent/metastatic undifferentiated nasopharyngeal carcinoma among young blacks in southern Africa.
Topics: Adolescent; Adult; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined | 1996 |
Pilot study of ambulatory infusional delivery of a multidrug regimen: ifosfamide, carboplatin and etoposide (ICE).
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Ambulatory Care; Anemia; Antineoplastic Combined Che | 1996 |
Ifosfamide and etoposide plus vincristine, doxorubicin, and cyclophosphamide for newly diagnosed Ewing's sarcoma family of tumors.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Cyclophosp | 1996 |
The limits of chemotherapy dose intensification using granulocyte colony stimulating factor alone in extensive small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Dose-Response Relationship, D | 1996 |
Prophylactic granulocyte colony-stimulating factor allows escalation of chemotherapeutic dose intensity in advanced epithelial ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cohort Studies; Combined Mod | 1996 |
Phase I dose-escalation trial of paclitaxel and ifosfamide in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Co | 1996 |
Phase II study of a closely spaced ifosfamide--cisplatin schedule with the addition of G-CSF in advanced non-small-cell lung cancer and malignant melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1996 |
Paclitaxel, ifosfamide and cisplatin with granulocyte colony-stimulating factor or recombinant human interleukin 3 and granulocyte colony-stimulating factor in ovarian cancer: a feasibility study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dose-Response Relationship, | 1997 |
Optimization of chemotherapy administration for clinical 41.8 degrees C whole body hyperthermia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Body Temperature; Breast Neoplasms; Carboplatin; Car | 1997 |
Phase II study of ifosfamide and etoposide chemotherapy for extensive-disease small-cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carcinoma, Small Cell; Drug Admin | 1997 |
A phase II trial of gemcitabine and ifosfamide in non-small cell lung cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Comb | 1997 |
Randomized open label phase III trial of CEOP/IMVP-Dexa alternating chemotherapy and filgrastim versus CEOP/IMVP-Dexa alternating chemotherapy for aggressive non-Hodgkin's lymphoma (NHL). A multicenter trial by the Austrian Working Group for Medical Tumor
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexametha | 1997 |
Clinical effects and pharmacokinetics of the fusion protein PIXY321 in children receiving myelosuppressive chemotherapy.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cisplati | 1998 |
Cisplatin, ifosfamide, and prolonged oral etoposide in the treatment of patients with extensive small cell lung carcinoma.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineo | 1998 |
A Phase I trial of ifosfamide and paclitaxel with granulocyte-colony stimulating factor in the treatment of patients with refractory solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Colonic Neoplasms; Fe | 1998 |
Integration of filgrastim into chemoradiation for limited small cell lung cancer: a Phase I study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Cohor | 1998 |
Phase I study on docetaxel and ifosfamide in patients with advanced solid tumours.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Feasibility Studies; Female; | 1998 |
A pilot study of vincristine, ifosfamide, and doxorubicin in the treatment of pediatric non-rhabdomyosarcoma soft tissue sarcomas.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Child; Child, Pr | 1998 |
Increased systemic toxicity of sarcoma chemotherapy due to combination with the P-glycoprotein inhibitor cyclosporin.
Topics: Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Membe | 1998 |
High-dose-intensity combination chemotherapy for advanced sarcomas: a pilot study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Dacarbazine; Doxorubicin; | 1998 |
High-dose ifosfamide plus adriamycin in the treatment of adult advanced soft tissue sarcomas: is it feasible?
Topics: Adolescent; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Feasib | 1998 |
Ifosfamide and vinorelbine: an active regimen for patients with relapsed or refractory Hodgkin's disease.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Female; Hodgkin Disease; Humans; Ifosfamide; | 1998 |
A pilot study of increasing dose intensity of epirubicin and ifosfamide in patients with small cell lung cancer by using recombinant granulocyte colony-stimulating factor.
Topics: Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemot | 1999 |
Moderate dose-escalation of combination chemotherapy with concomitant thoracic radiotherapy in limited-disease small-cell lung cancer: prolonged intrathoracic tumor control and high central nervous system relapse rate. Groupe d'Oncologie-Pneumologie Clini
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Combined M | 1999 |
Antitumoral activity of oxaliplatin/cisplatin-based combination therapy in cisplatin-refractory germ cell cancer patients.
Topics: Adolescent; Adult; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Ch | 1999 |
Ifosfamide and vinorelbine in metastatic breast cancer in patients with prior anthracycline therapy.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Asthenia; | 1999 |
Very intensive, short-term chemotherapy for children and adolescents with metastatic sarcomas.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bacteremia; Child; Child, Preschool; Cyc | 2000 |
Phase I study of dose-escalated paclitaxel, ifosfamide, and cisplatin (PIC) combination chemotherapy in advanced solid tumours.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dose-Response Relationship, | 2000 |
Prospective randomized comparison of morning versus night daily single subcutaneous administration of granulocyte-macrophage-colony stimulating factor in patients with soft tissue or bone sarcoma.
Topics: Adult; Anti-Bacterial Agents; Antineoplastic Agents, Alkylating; Bone Neoplasms; Chi-Square Distribu | 2000 |
A phase I dose escalation of combination chemotherapy with granulocyte-macrophage-colony stimulating factor in patients with neuroblastoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cisplati | 2000 |
Gemcitabine, ifosfamide, cisplatin (GIP) for the treatment of advanced non-small cell lung cancer: a phase II study of the italian oncology group for clinical research (GOIRC).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 2000 |
Cisplatin, ifosfamide, oral etoposide, and concurrent accelerated hyperfractionated thoracic radiation for patients with limited small-cell lung carcinoma: results of radiation therapy oncology group trial 93-12.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Chemoth | 2000 |
High dose ifosfamide in combination with etoposide and epirubicin followed by autologous stem cell transplantation in the treatment of relapsed/refractory Hodgkin's disease: a report on toxicity and efficacy.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Epirub | 2000 |
Phase II study with gemcitabine, ifosfamide and cisplatin in advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 2000 |
A randomized trial of amifostine as a cytoprotective agent in patients receiving chemotherapy for small cell lung cancer.
Topics: Adult; Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Sma | 2001 |
Prospective randomized trial between two doses of granulocyte colony-stimulating factor after ifosfamide, carboplatin, and etoposide in children with recurrent or refractory solid tumors: a children's cancer group report.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Child, Presch | 2001 |
Absence of major peripheral neuropathy in a phase II trial of ifosfamide with vinorelbine in patients with ovarian cancer previously treated with platinum and paclitaxel.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemother | 2001 |
Phase I trial of ifosfamide and 24-h infusional paclitaxel in pelvic malignancies: a Gynecologic Oncology Group study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Drug | 2001 |
Ifosfamide and mitoxantrone in the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Anemia; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, | 2001 |
Preclinical and clinical aspects on the use of amifostine as chemoprotector in neuroblastoma patients.
Topics: Adolescent; Amifostine; Animals; Antineoplastic Agents; Bone Marrow Diseases; Carboplatin; Cell Divi | 2001 |
Multiple cycles of dose-intensive chemotherapy with repeated stem cell support as induction treatment in metastatic breast cancer: a feasibility study.
Topics: Adult; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; | 2001 |
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid | 2001 |
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid | 2001 |
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid | 2001 |
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid | 2001 |
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid | 2001 |
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid | 2001 |
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid | 2001 |
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid | 2001 |
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid | 2001 |
Vinorelbine, ifosfamide and cisplatin as first-line treatment in patients with inoperable non-small cell lung cancer.
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lun | 2001 |
Combination chemotherapy with gemcitabine and ifosfamide as second-line treatment in metastatic urothelial cancer. A phase II trial conducted by the Hellenic Cooperative Oncology Group.
Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; He | 2001 |
Phase II/III trial of etoposide and high-dose ifosfamide in newly diagnosed metastatic osteosarcoma: a pediatric oncology group trial.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Disease-Fr | 2002 |
Ifosfamide and vinorelbine in advanced platinum-resistant ovarian cancer: excessive toxicity with a potentially active regimen.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Diseases; Drug A | 2002 |
[Effect of recombinant human granulocyte colony-stimulating factor (rG-CSF) on chemotherapy-induced neutropenia in patients with lung cancer].
Topics: Adenocarcinoma; Aged; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, No | 1990 |
46 other studies available for ifosfamide and Neutropenia
| Article | Year |
|---|---|
Body Mass Index as a Risk Factor for Toxicities in Patients with Advanced Soft-Tissue Sarcoma Treated with Trabectedin.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Agents, Alkylating; Antineoplastic Co | 2018 |
Safety and Cost-effectiveness of Outpatient Administration of High-dose Chemotherapy in Children With Ewing Sarcoma.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cost-Benefit An | 2019 |
Effects and toxicity of neoadjuvant chemotherapy preoperative followed by adjuvant chemoradiation in small cell neurdendocrine cervical carcinoma.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Neuroendo | 2015 |
[Efficacy and safety evaluation of gemcitabine combined with ifosfamide in patients with advanced nasopharyngeal carcinoma after failure of platinum-based chemotherapy].
Topics: Anemia; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Deoxycytid | 2015 |
Efficacy and tolerability of combination cisplatin and ifosfamide chemotherapy with vaginal cuff brachytherapy in the first line treatment of uterine carcinosarcoma.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Brachytherap | 2016 |
Clinical significance of a second-line chemotherapy regimen with paclitaxel, ifosfamide and nedaplatin for metastatic urothelial carcinoma after failure of cisplatin-based chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitio | 2016 |
Efficacy of Ifosfamide-Cisplatin-Etoposide (ICE) Chemotherapy for a CNS Germinoma in a Child With Down Syndrome.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Basal Ganglia; Cisplatin; Cranial Irradi | 2017 |
Aprepitant for the prevention of chemotherapy-induced nausea and vomiting in adolescents.
Topics: Adolescent; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Carboplatin; Ci | 2009 |
Population analysis of myelosuppression profiles using routine clinical data after the ICE (ifosfamide/carboplatin/etoposide) regimen for malignant gliomas.
Topics: Adult; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; | 2009 |
Paclitaxel combined with ifosfamide in anthracycline- and docetaxel-pretreated metastatic breast cancer: activity independence of prior docetaxel resistance.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docet | 2010 |
Comparison of long-term outcome between doublet and triplet neoadjuvant chemotherapy in non-metastatic osteosarcoma of the extremity.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Pre | 2011 |
High-dose ifosfamide as second- or third-line chemotherapy in refractory bone and soft tissue sarcoma patients.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Bone Neoplasms; Disease-Free Survival; Female; Human | 2011 |
Patterns of chemotherapy-induced toxicities in younger children and adolescents with rhabdomyosarcoma: a report from the Children's Oncology Group Soft Tissue Sarcoma Committee.
Topics: Adolescent; Age Factors; Anemia; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Presc | 2012 |
Uncaria tomentosa stimulates the proliferation of myeloid progenitor cells.
Topics: Administration, Oral; Animals; Cat's Claw; Cell Proliferation; Cells, Cultured; Disease Models, Anim | 2011 |
Lenograstim in preventing chemotherapy-induced febrile neutropenia in patients with soft tissue sarcoma.
Topics: Adjuvants, Immunologic; Adult; Aged; Antineoplastic Agents; Epirubicin; Female; Granulocyte Colony-S | 2013 |
[Continuous-infusion high dose ifosfamide as salvage treatment for pre-treated soft tissue sarcoma].
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Dose-Response Relationship, Drug; Female | 2002 |
Phase II study of induction chemotherapy with paclitaxel, ifosfamide, and carboplatin (TIC) for patients with locally advanced squamous cell carcinoma of the head and neck.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Clinical Tria | 2003 |
Salvage treatment with etoposide (VP-16), ifosfamide and cytarabine (Ara-C) for patients with recurrent primary central nervous system lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine | 2003 |
Hemopoietic recovery and infectious complications in breast cancer and multiple myeloma after autologous CD34+ cell-selected peripheral blood progenitor cell transplantation.
Topics: Adult; Aged; Antibiotic Prophylaxis; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasm | 2004 |
[Paclitaxel, ifosfamide, nedaplatin (TIN) for patients with metastatic urothelial cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Female; Humans; | 2004 |
[Treatment effect of DICE regimen on patients with relapsed or refractory intermediate and high grade non-Hodgkin's lymphoma].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Cisplatin; Dexametha | 2005 |
IIVP salvage regimen induces high response rates in patients with relapsed lymphoma before autologous stem cell transplantation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Etoposide; F | 2005 |
Acetaminophen-induced anion gap metabolic acidosis and 5-oxoprolinuria (pyroglutamic aciduria) acquired in hospital.
Topics: Acetaminophen; Acid-Base Equilibrium; Acidosis; Adult; Analgesics, Non-Narcotic; Antineoplastic Comb | 2005 |
[Salvage chemotherapy with paclitaxel, ifosphamide and nedaplatin for relapsed or refractory germ cell cancer].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Sc | 2006 |
[Effect of modified MAID regimen for patients with advanced soft tissue sarcoma].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Doxorubicin; F | 2006 |
[Efficacy of adriamycin, etoposide plus ifosfamide on small cell lung cancer--a retrospective analysis of 69 cases treated in Centre Hospitalo-Universitaire de Bordeaux].
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Doxorubi | 2006 |
IMVP-16: an effective regimen for patients with lymphoma who have relapsed after initial combination chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bacterial Infections; Cyclophosphamide; Drug | 1982 |
Mesna/ifosfamide, mitoxantrone, etoposide, bleomycin, vincristine, prednisone (MINE-BOP) combination chemotherapy in the treatment of refractory and relapsed non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Cytar | 1995 |
Chemoprophylaxis with oral ciprofloxacin in ovarian cancer patients receiving taxol.
Topics: Administration, Oral; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Bacteria | 1994 |
Treatment of advanced, high-grade soft-tissue sarcoma with ifosfamide and continuous-infusion etoposide.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Transfusion; Etoposide; Female; F | 1995 |
Failure of granulocyte-macrophage colony-stimulating factor to reduce febrile neutropenia in children with recurrent solid tumors treated with ifosfamide, carboplatin, and etoposide chemotherapy.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Child, Preschool; Et | 1994 |
Recurrent exacerbation of acne by granulocyte colony-stimulating factor administration.
Topics: Acne Vulgaris; Adolescent; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic | 1996 |
Ifosfamide, carboplatin, etoposide, and paclitaxel chemotherapy: a dose-escalation study.
Topics: Adult; Aged; Alopecia; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agen | 1996 |
The use of paediatric chemotherapy protocols at full dose is both a rational and feasible treatment strategy in adults with Ewing's family tumours.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; | 1997 |
[Pilot study of relapsed osteosarcoma and brain tumor with ifosfamide, carboplatin and etoposide (ICE therapy)].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; | 1998 |
[A case of neutropenic enterocolitis in high dose chemotherapy with peripheral blood stem cell transplantation for relapsed testicular tumor].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Enter | 1998 |
Evaluating a critically ill patient with metabolic acidosis: the ifosfamide paradigm.
Topics: Acidosis; Acidosis, Renal Tubular; Antineoplastic Combined Chemotherapy Protocols; Carbon Dioxide; C | 1999 |
Treatment of advanced soft tissue sarcomas with ifosfamide and doxorubicin combination chemotherapy.
Topics: Adolescent; Adult; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Co | 2000 |
Assessment of systemic toxicity in children receiving chemotherapy with cyclosporine for sarcoma.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplasti | 2000 |
Saccharomyces cerevisiae fungemia in a neutropenic patient treated with Saccharomyces boulardii.
Topics: Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Diarrhea; Etoposide; F | 2000 |
A three-drug regimen (gemcitabine, ifosfamide and cisplatin) for advanced non-small-cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deo | 2001 |
[Post-operative neoadjuvant chemotherapy before radiotherapy as compared to immediate radiotherapy followed by maintenance chemotherapy in the treatment of medulloblastoma in childhood: results of German prospective randomised trial HIT'91].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemotherapy, Adjuvant; | 2001 |
Ifosfamide, cisplatin, and etoposide (ICE) in the treatment of advanced non-small cell lung cancer.
Topics: Adult; Aged; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carcinoma | 1992 |
Carboplatin, etoposide, and ifosfamide as intensive chemotherapy for small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Com | 1990 |
A phase II study of ifosfamide, cisplatin, etoposide in patients with advanced non-small cell lung cancer: a preliminary report.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1990 |
Pilot study of neoadjuvant ifosfamide, cisplatin, and etoposide in locally advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1990 |